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Abstract
The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for
fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg
nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active
substances, the metabolic pathways in the chicken are similar to those in the turkey and rat.
Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC) and
2-hydroxy-4,6-dimethylpyrimidine (HDP) which behave independently. Monimax® does not represent a
genotoxic risk. No safety concerns would arise from the nicarbazin impurities p-nitroaniline and methyl
(4-nitrophenyl) carbamate. The lowest no observed effect level (NOEL) identiﬁed for monensin sodium
in a developmental study in rabbits is 0.3 mg monensin sodium/kg body weight (bw) per day for
maternal toxicity in rabbits. The lowest no observed adverse effect level (NOAEL) identiﬁed in a
52-week study in rat using DNC + HDP was 20 mg DNC + 8 mg HDP/kg bw per day based on the
absence of microcrystals in urine and related microscopic renal observations. No signiﬁcant interaction
between monensin sodium and nicarbazin is expected from toxicological studies. The use of Monimax®
at the highest proposed dose will not pose a risk to persons consuming animal products from treated
chickens for fattening. This conclusion is extended to chickens reared for laying. No withdrawal time is
required for Monimax® in chickens for fattening. Residue data comply with the established maximum
residue limits (MRLs) for monensin and DNC. Based on the available data, the FEEDAP Panel cannot
conclude on the safety of Monimax® for the environment. Monimax® has the potential to control
coccidiosis in chickens for fattening at a minimum concentration of 40 mg monensin and 40 mg
nicarbazin/kg complete feed.
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Summary
Following a request from European Commission, the Panel on Additives and Products or Substances
used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and efﬁcacy of
Monimax® (monensin sodium and nicarbazin), when used as a feed additive for chickens for fattening
and chickens reared for laying.
Monimax® is considered safe for chickens for fattening at the highest use level of 50 mg monensin
and 50 mg nicarbazin/kg complete feed. The margin of safety is about 1.5. This conclusion is extended to
chickens reared for laying. The simultaneous use of Monimax® and certain antibiotic drugs (i.e. tiamulin)
is contraindicated. Monensin has a selective antimicrobial activity against Gram-positive bacterial species
while many Enterobacteriaceae are naturally resistant. Induction of cross-resistance with clinically
relevant antimicrobials or increased shedding of enteropathogenic bacteria are not reported. Nicarbazin
has no antimicrobial activity.
Monensin sodium is absorbed at a limited extent and excreted rapidly, it is extensively metabolised
and gives rise to demethylated, oxidised and decarboxylated metabolites. Nicarbazin, when ingested, is
rapidly split in its two components dinitrocarbanilide (DNC) and 2-hydroxy-4,6-dimethylpyrimidine
(HDP) which behave independently. Liver is the target tissue. DNC residues decline rapidly from tissues
following nicarbazin withdrawal. DNC appears as the marker residue. HDP-related residues are much
lower than those derived from DNC. For both compounds of Monimax®, the metabolic pathways in the
chicken are similar to those in the turkey and rat.
The FEEDAP Panel concludes that the active substances in Monimax®, monensin sodium and
nicarbazin, do not represent a genotoxic risk. No safety concerns would arise from the nicarbazin
impurities p-nitroaniline (PNA) and methyl(4-nitrophenyl) carbamate (M4NPC). Monensin sodium has
no structural alert for carcinogenesis. Monensin sodium is not a reproductive or developmental
toxicant. The lowest no observed effect level (NOEL) identiﬁed in a developmental study in rabbits is
0.3 mg monensin sodium/kg body weight (bw) per day for maternal toxicity in rabbits. The primary
toxicity resulting from the oral use of nicarbazin is renal toxicity. The absence of similar ﬁndings after
treatment with DNC and HDP conﬁrms that this equimolar association of compounds is better tolerated
than nicarbazin at equivalent doses. The lowest NOAEL identiﬁed in a 52-week study in rat using
DNC + HDP was 20 mg DNC + 8 mg HDP/kg bw per day based on the absence of microcrystals in
urine and related microscopic renal observations. No signiﬁcant interaction between monensin sodium
and nicarbazin is expected from toxicological studies.
The use of Monimax® at the highest proposed dose (50 mg monensin and 50 mg nicarbazin/kg
complete feed) will not pose a risk to persons consuming animal products from treated chickens for
fattening. This conclusion is extended to chickens reared for laying up to 16 weeks of age. No safety
concern would arise from the impurity PNA if the maximum content in nicarbazin of 0.1% is respected.
The impurity M4NPC is considered safe for the consumer provided that a maximum concentration of 0.4%
in nicarbazin is not exceeded. No withdrawal time is required for Monimax® in chickens for fattening.
Residue data comply with the established maximum residue limits (MRLs) for monensin and DNC.
The monensin sodium contained in Monimax® presents a hazard by inhalation. Monimax® is not a
skin irritant; however, no data are available for the eye irritation potential of monensin. Monimax® may
also act as a dermal toxicant due to its monensin component. Monimax® is not a skin sensitiser.
The use of monensin sodium from Monimax® in complete feed for chickens for fattening does not
pose a risk for the aquatic compartment and sediment, while a risk cannot be excluded for the
terrestrial compartment. A ﬁnal conclusion on the risk resulting from the use of nicarbazin from
Monimax cannot be made because (i) DNC reﬁned predicted environmental concentrations (PECs)
show uncertainties linked to the very high persistence of the compound, (ii) DNC might accumulate in
the sediment compartment, and (iii) DNC can potentially bioaccumulate and may cause secondary
poisoning. No concerns would arise for the HDP moiety of nicarbazin excreted from chickens fed
Monimax®. These concerns prevent the FEEDAP Panel to draw a ﬁnal conclusion on the environmental
risk resulting from the use of Monimax® in chickens for fattening and chickens reared for laying.
The FEEDAP Panel concludes that Monimax® has the potential to control coccidiosis in chickens for
fattening at a minimum concentration of 40 mg monensin and 40 mg nicarbazin/kg complete feed.
This conclusion is extended to chickens reared for laying.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission (EC) received a request from the company Huvepharma N.V.2 for
authorisation of the product Monimax® (monensin sodium and nicarbazin), when used as a feed
additive for chickens for fattening and chickens reared for laying (category: coccidiostats and
histomonostats).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the
applicant the technical dossier in support of the application. The particulars and documents in support
of the application were considered valid by EFSA as of 31 January 2013.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Monimax® (monensin sodium and nicarbazin) when used under the proposed conditions of
use (see Section 3.1).
1.2. Additional information
The feed additive Monimax® containing two active substances, monensin sodium and nicarbazin, is
not authorised in the European Union. The safety and efﬁcacy of the additive for turkeys for fattening
has been recently assessed by the FEEDAP Panel (EFSA FEEDAP Panel, 2017).
There are two authorised coccidiostats containing monensin sodium: Coxidin®3 and Elancoban®.4
Both additives are authorised for their use in chickens for fattening, chickens reared for laying and
turkeys. The holder of the Coxidin® authorisation is Huvepharma N.V., the same applicant as that of
the current submission.
The Scientiﬁc Committee on Animal Nutrition (SCAN) issued two opinions in which monensin
sodium for its use in poultry (European Commission, 1981) and in turkeys (European Commission,
1983) was assessed. Coxidin® was evaluated by the EFSA Scientiﬁc Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP Panel) for chickens and turkeys for fattening (EFSA, 2005,
2006a), for turkeys (EFSA, 2007) and for chickens reared for laying (EFSA FEEDAP Panel, 2011a).
Elancoban® was evaluated for chickens for fattening, chickens reared for laying and turkeys for
fattening (EFSA, 2004a). Both products are currently under re-evaluation following Article 10(2) of
Regulation (EC) No 1831/2003. The maximum residue limits (MRLs) and withdrawal period for
monensin sodium in chickens for fattening and turkeys for fattening were evaluated by the FEEDAP
Panel in various scientiﬁc opinions (EFSA, 2006b, 2008a,b; EFSA FEEDAP Panel, 2013). Provisional
MRLs for monensin sodium in chickens for fattening, chickens reared for laying and turkeys for
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Uitbreidingstraat 80, 2600 Antwerp, Belgium.
3 Commission Regulation (EC) No 109/2007 of 5 February 2007 concerning the authorisation of monensin sodium (Coxidin) as a
feed additive. OJ L 31, 6.2.2007, p. 6. amended by Commission Regulation (EC) No 1095/2008 of 6 November 2008 amending
Regulation (EC) No 109/2007 as regards the terms of the authorisation of the feed additive monensin sodium (Coxidin). OJ L
298, 7.11.2008, p. 3. and Commission Implementing Regulation (EU) No 140/2012 of 17 February 2012 concerning the
authorisation of monensin sodium as a feed additive for chickens reared for laying (holder of authorisation Huvepharma NV
Belgium). OJ L 47, 18.2.2012, p. 18.
4 Commission Regulation (EC) No 1356/2004 of 26 July 2004 concerning the authorisation for 10 years of the additive
‘Elancoban’ in feedingstuffs, belonging to the group of coccidiostats and other medicinal substances. OJ L 251, 27.7.2004, p. 6.
amended by Commission Regulation (EC) No 108/2007 of 5 February 2007 amending Regulation (EC) No 1356/2004 as
regards the conditions for authorisation of the feed additive Elancoban, belonging to the group of coccidiostats and other
medicinal substances. OJ L 31, 6.2.2007, p. 4. and by Commission Regulation (EC) No 1096/2008 of 6 November 2008
amending Regulation (EC) No 1356/2004 as regards the terms of the authorisation of the feed additive ‘Elancoban’, belonging
to the group of coccidiostats and other medicinal substances. OJ L 298, 7.11.2008, p. 5.
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fattening, are in force: 25 lg monensin sodium/kg of wet skin + fat and 8 lg monensin sodium/kg of
wet liver, kidney and muscle5 ; the withdrawal time is one day before slaughter.6
There are two authorised coccidiostats containing nicarbazin: Koffogran7 (nicarbazin) and
Maxiban®8 (nicarbazin and narasin); both products are authorised for chickens for fattening only.
Koffogran has been assessed by the FEEDAP Panel (EFSA, 2004b and EFSA FEEDAP Panel, 2010a).
Maxiban® has been assessed by the SCAN (European Commission, 1991, 1995) followed by a FEEDAP
Panel assessment (EFSA FEEDAP Panel, 2010b). MRLs are in force for nicarbazin (dinitrocarbanilide
(DNC) as the marker residue) in chicken tissues: 15,000 lg DNC/kg of fresh liver, 6,000 lg DNC/kg of
fresh kidney, 4,000 lg DNC/kg fresh muscle and fresh skin + fat. The withdrawal time before slaughter
is one day for nicarbazin from Koffogran and zero day for nicarbazin from Maxiban®.9
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier10 in support of the authorisation request for the use of Monimax® (monensin sodium and
nicarbazin) as a feed additive. The technical dossier was prepared following the provisions of Article 7
of Regulation (EC) No 1831/2003 and the applicable EFSA guidance documents.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers and
other scientiﬁc reports.
EFSA has veriﬁed the EURL report as it relates to the methods used for the control of the active
substances in animal feed and the marker residues in tissues. The Executive Summary of the EURL
report can be found in Annex A.11
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Monimax®
(monensin sodium and nicarbazin) is in line with the principles laid down in Regulation (EC) No
429/200812 and the relevant guidance documents: Guidance for the preparation of dossiers for
coccidiostats and histomonostats (EFSA FEEDAP Panel, 2011b), Technical guidance: Tolerance and
efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011c), Technical Guidance for assessing the
safety of feed additives for the environment (EFSA, 2008c), Guidance for establishing the safety of
additives for the consumer (EFSA FEEDAP Panel, 2012a), Guidance on studies concerning the safety of
use of the additive for users/workers (EFSA FEEDAP Panel, 2012b), Technical Guidance: Microbial
Studies (EFSA, 2008d), Technical Guidance: Extrapolation of data from major species to minor species
regarding the assessment of additives for use in animal nutrition (EFSA, 2008e) and Guidance on the
assessment of bacterial susceptibility to antimicrobials of human and veterinary importance (EFSA
FEEDAP Panel, 2012c).
3. Assessment
Monimax® (monensin sodium and nicarbazin) is intended to be used as a coccidiostat in feed for
chickens for fattening and chickens reared for laying for the control of coccidiosis.
5 OJ L 31, 6.2.2007, p. 6. and OJ L 47, 18.2.2012, p. 18.
6 OJ L 298, 7.11.2008, p. 3. and OJ L 47, 18.2.2012, p. 18.
7 Commission Regulation (EU) No 875/2010 of 5 October 2010 concerning the authorisation for 10 years of a feed additive in
feedingstuffs. OJ L 263, 6.10.2010, p. 4.
8 Commission Regulation (EU) No 885/2010 of 7 October 2010 concerning the authorisation of the preparation of narasin and
nicarbazin as a feed additive for chickens for fattening (holder of the authorisation Eli Lilly and Company Ltd) amending
Regulation (EC) No 2430/1999. OJ L 265, 8.10.2010, p. 5.
9 OJ L 263, 6.10.2010, p. 4. and OJ L 265, 8.10.2010, p. 5.
10 FEED dossier references: FAD-2012-0027.
11 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnrep-fad-2012-0027-monimax.pdf
12 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No
1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and
the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
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3.1. Characterisation
The additive Monimax® contains as active substances monensin sodium and nicarbazin. Monensin
sodium is a polyether ionophore produced by fermentation from a culture of Streptomyces spp.13
Nicarbazin is an equimolar complex of 1,3-bis(4-nitrophenyl)urea, also known as N,N’-bi(4-nitrophenyl)
urea or 4,40-dinitrocarbanilide (DNC) and 4,6-dimethylpyrimidin-2-ol (HDP). The composition is
reported in Table 1.
The identity of the additive, characterisation of the active substance, manufacturing process and
technological properties of the additive have been recently reviewed by the FEEDAP Panel; the
production strain has been also characterised and assessed (EFSA FEEDAP Panel, 2017).
Monimax® is intended to be used to prevent coccidiosis in chickens for fattening and chickens
reared for laying. The recommended inclusion level of Monimax® in complete feed for chickens for
fattening and for chickens reared for laying up to 16 weeks of age is 40 + 40 to 50 + 50 mg
monensin + nicarbazin/kg. The applicant proposes a withdrawal period of 1 day.
MRLs for edible chicken tissues are proposed (15,000 lg DNC/kg of fresh liver, 6,000 lg DNC/kg of
fresh kidney, 4,000 lg DNC/kg fresh muscle and fresh skin + fat).
3.2. Safety
3.2.1. Safety for the target species
3.2.1.1. Tolerance study in chickens for fattening
A total of 224 one-day-old male and female chickens for fattening (Ross 308) was randomly
allocated to four groups with four replicates per sex (ﬁve birds + two spare birds for the ﬁrst week/
replicate) each fed diets containing 0, 60 + 60 (1.29 maximum proposed level), 75 + 75 (1.5x) and
100 + 100 (2x) mg monensin + nicarbazin/kg complete feed, respectively, for 42 days.14 The basal
diet consisted mainly of wheat, soya and maize.15 Nutrient contents of both starter and grower diets
were not provided. The starter diet was fed as crumbles for 14 days; the grower as pellets until the
end of the study. The birds had ad libitum access to feed and water. The intended concentrations of
monensin and nicarbazin in the starter and the grower diet were analytically conﬁrmed.
Clinical observations were made daily; body weight and feed intake were recorded at weekly
intervals. On day 39, blood samples were taken from one bird per replicate (four males and four
females per treatment) for haematology16 and clinical blood biochemistry.17 On day 42, one bird/
replicate was killed and subjected to necropsy, organ weights were determined for heart, liver, kidneys
and spleen. Histopathology was performed for duodenum, ileum, caeca, colon, liver, kidneys, spleen,
Table 1: Composition of Monimax®
Ingredients g/kg Monimax®
Active ingredients
Monensin(1) 80
Nicarbazin(2) 80
Other ingredients
Starch for granulation 15
Wheat meal 580
Calcium carbonate q.s. 1,000
(1): From monensin sodium technical substance containing ≥ 27% monensin activity.
(2): From nicarbazin containing ≥ 95.1% nicarbazin.
13 Technical dossier/Section II/Annex II.17.
14 Technical dossier/Section III/Annex III.1.
15 Technical dossier/Supplementary information February 2017/Annex 12.
16 Red blood count (RBC), haematocrit, haemoglobin, mean corpuscular haemoglobin (MCH), mean corpuscular volume (MCV),
mean corpuscular haemoglobin concentration (MCC), thrombocyte (TBH), white blood cell (WBC) count: heterophils,
eosinophils, basophils, monocytes and lymphocytes).
17 Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH),
creatine kinase (CK), total protein, total bilirubin, bile acids (BIAC), total cholesterol, glucose, calcium, inorganic phosphorus,
magnesium, sodium, potassium, chloride, uric acid, creatinine.
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heart and lungs. Two separate statistical analyses were provided; the ﬁrst one based on separate
datasets for male and female birds, and the second one on all birds.18 Both analyses were based on
analysis of variance (ANOVA) after veriﬁcation the normal distribution and the homogeneity of the
data. If the conditions for applying an ANOVA were not proved nonparametric procedures (i.e.
Kruskal–Wallis one-way analysis of variance on ranks, Shirley’s or Steel’s test) were applied. Covariance
analysis was applied to organ weights, and the Fisher’s exact test to clinical pathology. Group
comparisons were done by the Tukey’s test/Dunnett’s method.
Four birds in the high-dose group died without preceding clinical symptoms. The main results of the
study are summarised in Table 2.
A signiﬁcant growth depression was observed in the high-dose female group compared to the
control group. Feed to gain ratio was also inferior in the high-dose groups, but signiﬁcant only for
males. However, a combined evaluation of both sexes (mean body weights for the four groups were
2,187, 2,150, 2,191 and 2,025 g, respectively; mean feed to gain ratios were 1.67, 1.74, 1.72 and
1.83, respectively) did not indicate signiﬁcant differences compared to the control group for both
endpoints due to treatment or pen.
All treated groups showed a signiﬁcantly lower level of white blood cells (WBC), compared with the
control group, by both statistical methods. However, it was noted that the control values for WBC are
high compared to historical data of the applicant (11.7 and 13.0 9 109/L for females and males,
respectively).19 All treated groups showed signiﬁcantly lower numbers of heterophils by both statistical
methods (mean values were 7.97, 4.79, 4.40 and 3.82 109/L for control, and the groups treated with
60 + 60, 75 + 75 and 100 + 100 mg monensin + nicarbazin/kg, respectively). Thrombocytes were
signiﬁcantly higher for females in all treated groups and for males in the high-dose group only. Group
averages of all treated groups (13.0, 11.0, 13.0 109/L) were signiﬁcantly higher than the control group
value (8.5 109/L). The differences in heterophils and thrombocytes showed no dose relationship
(conﬁrmed by a separate ANOVA followed by Tukey’s test for the treated groups (group means and
gender subgroups) only). Thus, the statistical differences are considered to reﬂect a control group with
values at the ends of the normal range.
Most clinical biochemical parameters (ALP, ALT, AST, LDH, CK, bilirubin, cholesterol, Na, K, Cl, Mg,
uric acid, creatinine, glucose, total proteins, albumin) remained unchanged in treated groups when
compared with controls. Signiﬁcant differences were recorded for bile acid, phosphorus and albumin/
globulin ratio. Bile acid and phosphorus values were higher in the intermediate-dose group (17.25 vs
Table 2: Main results of a 6-week tolerance study in chickens for fattening with Monimax®
Mo + Ni
(mg/kg
feed)(1)
0 + 0 60 + 60 75 + 75 100 + 100
Sex Male Female Male Female Male Female Male Female
Final body
weight (g)
2,250 2,124 2,214 2,085 2,305 2,076 2,180 1,869*
Feed intake
(g/bird
and day)
88 90 89 96 94 92 96 84
Feed to
gain ratio
1.62 1.71 1.65 1.83 1.67 1.77 1.81* 1.85
WBC (109/L) 18.75 17.81 13.75* 11.65* 11.56* 13.75* 10.31* 11.56*
Lymphocytes
(109/L)
7.75 8.50 6.64 5.30 5.95 7.27 4.97 6.29
Heterophils
(109/L)
8.84 7.09 5.29* 4.29* 3.89* 4.90* 4.05* 3.60*
Thrombocytes
(109/L)
7 9 11 14* 12 12* 15* 23*
(1): Mo: monensin; Ni: nicarbazin.
*: Signiﬁcant change compared to the control within sex (p ≤ 0.05).
18 Technical dossier/Supplementary information February 2017/Annex 13.
19 Technical dossier/Supplementary information June 2015/Annex I.
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12.26 lmol/L for bile acid and 2.72 vs 2.35 mmol/L for P) than in the control group but there was no
dose-related effect and the values in the use level and high-dose groups (14.83 and 13.43 mg lmol/L
for bile acid and 2.38 and 2.35 mmol/L for P, respectively) did not differ when compared with controls.
The values remained in the physiological range. The difference is most probably a random effect
reaching accidentally signiﬁcance. The albumin/globulin ratio was signiﬁcantly higher in the high-dose
group when compared with control animals. The difference remained marginal (1.036 vs 0.936 in
controls), its toxicological signiﬁcance is questionable.
No signiﬁcant differences in organ weights were found (both statistical analyses). Macro- and
histopathology did not indicate any potentially relevant treatment effect.
Conclusions
Feeding the twofold of the highest proposed use level of Monimax® (100 + 100 mg
monensin + nicarbazin/kg) resulted in a reduction of the zootechnical performance. No such effects were
seen at 75 + 75 mg monensin + nicarbazin/kg complete feed. Although some differences were seen
between treated and control groups in values from haematology and clinical blood chemistry, the FEEDAP
Panel considers that these are within the normal range and of questionable toxicological signiﬁcance.
Monimax® at the highest proposed dose (50 + 50 mg monensin + nicarbazin/kg complete feed) is
considered safe for chickens for fattening with a margin of safety of about 1.5.
3.2.1.2. Interactions
Interactions between the polyether ionophore coccidiostats and the diterpene antibiotic tiamulin as
well as other antimicrobials (mainly macrolides) were already described by the FEEDAP Panel in 2004
(EFSA, 2004c). Therefore, the simultaneous use of monensin and certain antibiotic drugs (i.e. tiamulin)
is contraindicated. The same contraindications would also apply to Monimax® due to its monensin
content. However, since this interaction is dose-dependent, it could be expected that the lower feed
concentration of monensin from Monimax® would result in reduced severity of interactions.
3.2.1.3. Microbiological safety of the additive
The microbiological safety of monensin sodium and nicarbazin has been assessed recently (EFSA
FEEDAP Panel, 2017). The FEEDAP reiterates the same conclusions for the current assessment:
monensin has a selective antimicrobial activity against Gram-positive bacterial species while many
Enterobacteriaceae are naturally resistant. The use of monensin as a feed additive is not expected to
increase shedding of enteropathogens and to induce resistance or cross-resistance to antimicrobials
used in human and animal therapy. Nicarbazin has no antimicrobial activity.
3.2.1.4. Conclusions on the safety for the target species
The highest use level, 50 mg monensin and 50 mg nicarbazin/kg complete feed is considered safe
for chickens for fattening with a margin of safety of about 1.5. The conclusions reached in chickens for
fattening are extended to chickens reared for laying.
The simultaneous use of Monimax® and certain antibiotic drugs (i.e. tiamulin) is contra-indicated.
Monensin has a selective antimicrobial activity against Gram-positive bacterial species while many
Enterobacteriaceae are naturally resistant; induction of cross-resistance with clinically relevant
antimicrobials or increased shedding of enteropathogenic bacteria was not reported. Nicarbazin has no
antimicrobial activity.
3.2.2. Safety for the consumer
3.2.2.1. Absorption, distribution, metabolism and excretion
Monensin sodium
Data concerning the metabolic fate of monensin sodium in chicken, turkey and rat were submitted
in former dossiers of Coxidin® and were assessed by the FEEDAP Panel (EFSA, 2005, 2006a). For
the present assessment, the same conclusions can be retained which can be summarised as follows:
(i) monensin sodium is absorbed to a limited extent and this fraction is eliminated largely through bile,
(ii) monensin sodium is metabolised extensively and gives rise to demethylated, oxidised and
decarboxylated metabolites, (iii) unchanged monensin represents about 19% of the whole faecal
excretion in chicken, up to 40% in turkey (iv) the same metabolites have been found in the excreta
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and tissues where they represent each less than 10% of the total monensin derivatives, and (v) the
metabolic pathways in the chicken are similar to those in the turkey and rat.
A recent study of the metabolism of monensin sodium in chickens was submitted.20 Chickens (3
males and 3 females) were administered for eight consecutive days, by gavage and twice a day, 14C-
monensin sodium at a nominal dose corresponding to 125 mg/kg feed (analytically conﬁrmed). The
excreta were collected each day and 24 h after the last dose. Tissues were collected from birds
slaughtered at 1, 3 and 6 h after the last dose. Monensin and metabolites were analysed by liquid
chromatography–mass spectrometry (LC–MS). Monensin amounted to 28–31% of the radioactivity
excreted, all metabolites being below 10%. Metabolites in tissues and excreta were identiﬁed as
demethylated forms of monensin and (mono- and di-) hydroxylated monensin (hydroxylation positions
not established). These ﬁndings are in line with the previous conclusions.
Nicarbazin
Nicarbazin is entirely split in the intestinal tract of birds into its two constituents, DNC and HDP.
Consequently, nicarbazin cannot appear as residue in tissues and is therefore of no concern for
consumer safety; only its two individual components may generate residues.
Absorption, distribution, metabolism and excretion (ADME) studies including total residue
determination have been performed with [14C]-DNC nicarbazin and [14C]-HDP nicarbazin administered
in feed under powder form to avoid splitting of the molecular complex in solution (e.g. water or
solvent like dimethyl sulfoxide (DMSO) used for gavage). A comparative in vitro study of the
metabolism of nicarbazin in chicken, turkey and rat hepatocytes was also provided.
[14C]-DNC nicarbazin21
In a Good Laboratory Practice (GLP) study, chickens (24-day-old chickens, 3 males and 3 females
per group) were administered nicarbazin (both unlabelled and [DNC-phenyl-U-14C]-nicarbazin) and
monensin sodium, each at a nominal level of 55 mg/kg feed (analytically conﬁrmed), for 10
consecutive days to reach steady state. Animals were slaughtered after 0.25-, 1- and 2-day additive
withdrawal. Identity of metabolites in tissues was examined using liquid chromatography with tandem
mass spectrometry (LC–MS/MS) analysis and synthesised reference compounds. After 0.25-day
withdrawal time, the metabolic proﬁle was similar in liver, muscle and skin/fat with DNC being the main
component detected (68%, 80% and 95%, respectively). 4-Acetylamino-40-nitrocarbanilide, resulting
from the reduction of one nitro group and its subsequent acetylation, represented 18% of the total
radioactivity in liver and 10% in muscle. 4,40-Diacetylamino-carbanilide, resulting from the reduction
and acetylation of the two nitro groups, amounted to 12% of the total radioactivity in muscle,
4-acetylamino-40-nitrocarbanilide up to 10% and an unknown component 12%. In the kidney,
4,40-diacetylamino-carbanilide was the main component (54%), followed by N,N’-1,4-phenylenebis-
acetamide (27%) resulting from the split of the molecule and DNC (14%).
[14C]-HDP-nicarbazin22
A GLP study following the same experimental design as for the DNC study described above, was
performed using [HDP-pyrimidyl-2-14C]-nicarbazin. Identiﬁcation of HDP and metabolites in tissues was
performed using LC–MS/MS analysis. After 0.25-day withdrawal time, HDP appeared to be the major
compound in the liver of males and females (60% and 53% of total radioactivity, respectively), one
major metabolite representing 40% and 37%, and another metabolite 11% (in females only). HDP
prevailed in the kidney (92%, average of male and female), muscle (99%) and skin/fat (88%),
metabolites being ˂ 10%. None of the metabolites were identiﬁed.
In vitro comparison of the metabolic fate of DNC and HDP in chicken, turkey and rat hepatocytes23
An in vitro comparison of the metabolic fate of DNC in cryopreserved hepatocytes of chicken,
turkey and rat was performed, based on high-performance liquid chromatography with high-resolution
tandem mass spectrometry (HPLC-high-resolution MS/MS) analysis. Seven to eight metabolites were
isolated from hepatocyte incubations of the three species, separated and tentatively identiﬁed. The
main metabolites produced in vivo and already described were identiﬁed in vitro. Hydroxylation
(position not established) followed by glucuronidation or sulfation and glucuronidation of secondary
20 Technical dossier/Supplementary information June 2015/Annex VII_Reference 5.
21 Technical dossier/Supplementary information February 2017/Annex 14.
22 Technical dossier/Supplementary information February 2017/Annex 15.
23 Technical dossier/Supplementary information February 2017/Annex 16.
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amine function were also identiﬁed. A large overlap but also differences were observed between
animal species. Qualitatively the main enzymes involved in DNC metabolism are nitro-reductase and
N-acetyl transferases in chicken, nitro reductase, N-acetyl transferases, oxidase and UGTs in turkey
and oxidase and UGTs in rat hepatocytes. Quantitatively, no signiﬁcant difference was observed in the
amount of DNC metabolised over time between chicken and turkey.
The in vitro metabolism of HDP by chicken, turkey and rat cryopreserved hepatocytes was
investigated in the same study using the same experimental design and the analytical approaches used
to characterise DNC and metabolites. Only unreacted HDP was detected in any incubation analysed,
indicating the absence of signiﬁcant biotransformation of HDP in the three species.
In conclusion, the metabolic pathways in the chicken are similar to those in the turkey and rat.
3.2.2.2. Residues in tissues
Residue studies were performed with the additive Monimax® to investigate the total and marker
residue concentrations in tissues of chickens for fattening.
Monensin
Monensin residues in poultry tissues were determined by LC–MS/MS analytical method with a limit
of quantiﬁcation (LOQ) of 0.0005 mg/kg for all tissues.
In a monensin residue study, chickens (3 males and 3 females day-old per group) were
administered feed containing 50 + 50 mg monensin + nicarbazin from Monimax®/kg (analytically
conﬁrmed) for 42 days and slaughtered after 6 h (0.25-day withdrawal).24 Average monensin
concentration was 0.008  0.002 mg/kg in the skin/fat and below the LOQ in the liver, kidney and
muscle.
In another monensin residue study, chickens (3 males and 3 females, day-old per group) were
administered feed containing 50 + 50 mg monensin sodium + nicarbazin from Monimax®/kg
(analytically conﬁrmed) for 36 days.25 The animals were slaughtered after 3, 18, 24 and 48 h
withdrawal. After a 3-h withdrawal period, analysis of monensin in tissues showed values of 0.0015
mg/kg liver, 0.0017 mg/kg kidney, 0.0025 mg/kg muscle and 0.0074 mg/kg skin/fat.
Nicarbazin
DNC
In a GLP study,26 chickens (24-day-old, 3 males and 3 females per group) were administered
nicarbazin (both unlabelled and [DNC-phenyl-U-14C]-nicarbazin) and monensin sodium, each at a
nominal level of 55 mg/kg feed (analytically conﬁrmed), for 10 consecutive days. Animals were
slaughtered after 6, 12 and 48 h (0.25-, 1- and 2-day withdrawal). Total and marker residue
concentrations declined rapidly following nicarbazin withdrawal. The results of total residues and
marker residue measured after a 0.25-day withdrawal period are presented in Table 3.
Table 3: Total residues (expressed as mg equivalent DNC/kg fresh tissue) and marker residue
measured in tissues from chickens (3 males and 3 females) administered for 10 days 55
mg 14C-DNC-nicarbazin and 55 mg monensin sodium/kg feed in powder form, following a
0.25-day withdrawal period
Liver Kidney Muscle Skin/fat
TRC(1) (mg/kg)  SD 14.637  2.149 9.705  1.733 2.154  0.596 2.750  0.600
TRC  2SD 18.9 13.2 6.1 4.0
MRC(2) (mg/day)  SD 6.857  0.920 0.806  0.584 0.761  0.207 1.269  0.326
MRC  2SD 8.7 2.0 1.2 1.9
RMTR(3) 0.47 0.08 0.35 0.46
(1): Total residue concentration.
(2): Marker residue concentration.
(3): Ratio marker to total residues at 0.25-day withdrawal time.
24 Technical dossier/Section III/Annex III.8.
25 Technical dossier/Section III/Annex III.6.
26 Technical dossier/Supplementary information February 2017/Annex 18.
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Marker residue studies were provided for chickens for fattening.27 Birds (3 males and 3 females,
day-old) were fed a diet containing Monimax® (50 + 50 mg monensin + nicarbazin/kg feed). The
duration was 35 days.
DNC and HDP residues were analysed by LC–MS/MS analysis with LOQs of 0.1 and 0.11 mg/kg for
all tissues, respectively. Mean DNC concentrations plus 2SD measured in the liver, kidney, muscle and
skin/fat after 0.25-day withdrawal were 8.331, 1.514, 1.182 and 1.723 mg DNC/kg tissue, respectively.
Average HDP concentrations were 0.117 mg/kg in the liver and below the LOQ in the kidney, muscle
and skin/fat.
HDP
The quantiﬁcation of total residues in tissues resulting from the administration of 14C-HDP-
nicarbazin to chickens was addressed in the study described above.26 The results corresponding to
0.25-day withdrawal period are presented in Table 4.
HDP residues are 221, 87, 41 and 46 times lower than the corresponding DNC residues.
3.2.2.3. Residues in eggs
From a study assessed by the FEEDAP Panel in 2011, monensin residues in eggs of chickens reared
for laying fed diets containing monensin from Coxidin® at onset of laying were below the LOQ (EFSA
FEEDAP Panel, 2011a).
A study was performed to determine the marker residue of nicarbazin (DNC) in the ﬁrst eggs laid
by chickens reared for laying.28 Three groups of animals (12 per group, day-old) were fed a blank feed
until 8 weeks of age, followed by the administration of a complete feed supplemented with 50 mg
nicarbazin from Monimax®/kg (analytically veriﬁed) for 4, 6 and 8 weeks ending to 12, 14 and 16
weeks of age, respectively. From the end of the Monimax® feeding period until onset of laying, a blank
feed was given. The ﬁrst 20 eggs after onset of laying were collected of which ten eggs were analysed
(mixed yolk and albumen of each egg) by LC–MS/MS (LOQ of 0.005 mg/kg whole egg, limit of
detection (LOD) of 0.0005 mg/kg) for DNC content. In the group of 16-week old birds (8 weeks
exposure to Monimax®), the ﬁrst three eggs collected 9, 12 and 14 days after withdrawal showed DNC
residues of 0.260, 0.044 and 0.027 mg/kg, respectively, the seven eggs collected later were below the
LOQ. No residues were detected in all eggs collected in the groups corresponding to 14- and 12-week
animals.
3.2.2.4. Toxicological studies
The toxicity of nicarbazin and monensin sodium was assessed by the FEEDAP Panel in 2017 (EFSA
FEEDAP Panel, 2017) and it was concluded that:
Monensin sodium is not genotoxic in an adequate range of studies and has shown no structural
alert for carcinogenesis. Monensin sodium is not a reproductive or developmental toxin based on
adequate current studies in rat and rabbit. The lowest NOEL identiﬁed in the developmental study in
rabbits is 0.3 mg monensin sodium/kg bw per day for maternal toxicity in rabbits.
Nicarbazin showed mutagenic activity in the Salmonella Typhimurium TA98 strain in the presence
and in the absence of metabolic activation, while the substance was negative in the other bacterial
strains. Negative results were reported also in a gene mutation assay in L5178Y TK+/ mouse
lymphoma cells and in a chromosome aberration test in human lymphocytes in vitro. Moreover
nicarbazin did not show any mutagenic activity in an in vivo micronucleus test in rat in conditions
Table 4: Total residues (expressed as mg equivalent HDP/kg fresh tissue) measured in tissues from
chickens administered for 10 days 55 mg 14C-HDP-nicarbazin and 55 mg monensin
sodium/kg feed under powder form, following a 0.25-day withdrawal period
Liver Kidney Muscle Skin/fat
TRC (mg/kg)  SD 0.065  0.019 0.111  0.032 0.053  0.032 0.060  0.018
TRC  2SD 0.103 0.175 0.085 0.096
TRC: total residue concentration.
27 Technical dossier/Supplementary information February 2017/Annex 17.
28 Technical dossier/Supplementary information January 2014/Annex 4.
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warranting the exposure of the target cells to the test substance. The primary toxicity resulting from
the oral use of nicarbazin is renal toxicity. The absence of similar ﬁndings after treatment with DNC
and HDP conﬁrms that this equimolar association of compounds is better tolerated than nicarbazin at
equivalent doses. At parentally toxic doses (renal effects) there is no impairment of reproductive
performance in rats treated with a combination of DNC/HDP at doses up to 580/193 mg/kg bw per
day. The NOAEL for embryo/foetal development is 120 mg nicarbazin/kg bw of rabbits per day. The
lowest NOAEL identiﬁed in a 52-week study in rat using DNC + HDP was 20 mg DNC + 8 mg HDP/kg
bw per day based on the occurence of microcrystals in urine and related microscopic renal
observations at higher dose level.
When the combination of monensin sodium and DNC + HDP was tested in a bacterial reverse
mutation test, the results were consistent with the ﬁndings of separate tests with monensin sodium and
nicarbazin. The FEEDAP Panel concludes that the active substances in Monimax®, monensin sodium
and nicarbazin, do not represent a genotoxic risk. Furthermore, there was no evidence resulting from
the toxicological studies for any signiﬁcant interaction between monensin sodium and nicarbazin’.
The toxicity of the nicarbazin impurities, p-nitroaniline (PNA) and methyl(4-nitrophenyl) carbamate
(M4NPC), were assessed in the same opinion (EFSA FEEDAP Panel, 2017) and it was concluded that
no safety concerns would arise from the nicarbazin impurities PNA and M4NPC in Monimax®.
3.2.2.5. Assessment of consumer safety
For monensin, the current provisional MRLs in chickens for fattening (25 lg/kg wet skin + fat and
8 lg/kg wet liver, kidney and muscle) ensure consumer safety. Residue data obtained for monensin
after the use of the highest proposed level of Monimax® in feed (50 + 50 mg monensin + nicarbazin/
kg) for chickens for fattening (Section 3.2.2.2) showed that after withdrawal times of 3 and 6 h in
chickens all marker residue concentrations were below the respective MRLs in liver, kidney, muscle and
skin + fat. The withdrawal times applied are considered equivalent to 0-day under practical conditions.
As the consumer will not be exposed to nicarbazin but to DNC and HDP, and DNC residues are orders
of magnitude higher than HDP residues (see Tables 3 and 4), DNC is considered the marker residue.
A health-based guidance value (acceptable daily intake (ADI)) for the nicarbazin moieties (DNC and
HDP) can be derived from the NOAEL of 20 mg DNC and 8 mg HDP/kg body weight (bw) based on
the absence of microcrystals in the urine obtained in a 52-week study in rat using DNC + HDP. The
ADI is 0.2 mg DNC and 0.08 mg HDP/kg bw applying an uncertainty factor of 100.
Exposure of the consumer to DNC was calculated applying the food basket of Regulation (EC)
No 429/2008 (Table 5).29 Consumer exposure to total DNC residues from chicken tissues showed
compliance with the ADI (35%) after practical 0-day withdrawal. Similar calculation carried out with
HDP total residues (from Table 5) indicates compliance with the corresponding ADI (dietary intake of
HDP total residues is 0.047 mg/day corresponding to about 1% of the ADI).
For nicarbazin, MRLs for DNC of 15 mg/kg liver, 6 mg/kg kidney and 4 mg/kg muscle and skin/fat in
chickens for fattening are in force at EU level. Although these MRLs were derived from an ADI of
0.77 mg DNC/kg bw per day, they comply with the newly derived ADI (see Table 5). Calculation of
consumer exposure, using the MRLs and applying the ratio marker to total residues (RMTR) of the
recent residue study in chickens (Section 3.2.2.2), results in an exposure of about 70% of the new ADI.
Compliance with the MRLs is given at zero day withdrawal time.
Table 5: Consumer exposure to DNC in tissues of chickens for fattening and compliance with the
ADI
Liver Kidney Muscle Skin/fat Sum
TRC (mg/kg) + 2SD 18.9 13.2 6.1 4.0
DITR(1) (mg/day) 1.89 0.13 1.83 0.36 4.21 (35% ADI)
RMTR(2) 0.47 0.08 0.35 0.46
MRL (mg/kg) 15 6 4 4
DITRMRL(3) (mg/day) 3.2 1 3.4 0.8 8.4 (70% ADI)
(1): Dietary intake of total residues.
(2): Ratio marker to total residues at 0.25 day withdrawal time.
(3): Dietary intake of total residues calculated from the MRLs.
29 OJ L 133, 22.5.2008, p. 1.
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Monensin residues in eggs of chickens reared for laying fed diets containing 125 mg monensin from
Coxidin®/kg feed at onset of laying were below the limit of quantiﬁcation in a study assessed in 2011
(EFSA FEEDAP Panel, 2011a). Considering that the dose of monensin sodium from the use of
Monimax® is lower (50 mg monensin/kg feed), no safety concern is expected for the consumer of
eggs from chickens fed Monimax® under the proposed conditions of use. Consumer exposure to DNC
by the use of Monimax® at the maximum applied use level for chickens reared for laying from the ﬁrst
egg laid 9 days after cessation of the supplemented feed (given up to 16 weeks of age) would be
negligibly low compared to the intake from chicken tissues (0.03 mg vs. 4.21 mg DNC/person per day
applying the food basket of Regulation (EC) No 429/2008 for eggs).
No residues were found in chicken muscle and kidney (< 0.002 mg/kg), when exposed to about the
ﬁvefold M4NPC dietary level compared to the highest use level applied for Monimax®; residues in liver
and skin/fat were 0.009 and 0.013 mg/kg, respectively. Consequently, M4NPC in Monimax® is
considered safe for the consumer provided that a maximum concentration of 0.4% in nicarbazin would
not be exceeded. No safety concern would arise from the impurity PNA if the maximum content in
nicarbazin of 0.1% is respected.
3.2.2.6. Conclusions on the safety for the consumer
The use of Monimax® at the highest proposed dose (50 + 50 mg monensin + nicarbazin/kg
complete feed) will not pose a risk to persons consuming animal products from treated chickens for
fattening. This conclusion is extended to chickens reared for laying up to 16 weeks of age.
No safety concern would arise from the impurity PNA if the maximum content in nicarbazin of 0.1%
is respected. The other nicarbazin related impurity, M4NPC, is considered safe for the consumer
provided that a maximum concentration of 0.4% in nicarbazin would not be exceeded.
No withdrawal time is required for Monimax® in chickens for fattening.
3.2.3. Safety for the user
The safety for the user of Monimax® has been assessed recently (EFSA FEEDAP Panel, 2017). The
FEEDAP reiterates the same conclusions for the current assessment.
‘In the absence of data performed with Monimax®, the FEEDAP concluded on the safety for the
user based on the data available on its individual components. The monensin sodium contained in
Monimax® presents a hazard by inhalation. Although the dusting potential of Monimax® is low, users
will be exposed to monensin by inhalation indicating a risk to persons handling Monimax®.
Monimax® is not a skin irritant; however, no data are available for the eye irritation potential of
monensin. Monimax® may also act as a dermal toxicant due to its monensin component. Monimax® is
not a skin sensitiser’.
3.2.4. Safety for the environment
Active substances are not physiological/natural substances of established safety for the
environment. The additive is also not intended for companion animals. Consequently, according to
Regulation (EC) No 429/200829 the Phase I assessment has to be continued to determine the
predicted environmental concentration.
In Phase I and II initially a total residues approach will be taken, meaning that the predicted
environmental concentrations (PECs) will be calculated, based on the assumption that the additives are
excreted 100% as parent compound. Nicarbazin is an equimolar complex of DNC and HDP in a 70:30
w/w ratio, which splits during the intestinal passage. Consequently, the environmental risk assessment
should not consider nicarbazin but both components separately. Distribution in the environment is
based on the properties of the individual components of Monimax® as long as no data on relevant
metabolites and on potential interaction are submitted.
MONENSIN SODIUM
3.2.4.1. Phase I
Physico-chemical properties
The physical–chemical properties of monensin sodium are summarised in Table 6. The dissociation
constant pKa was not provided by the applicant but Sun et al. (2016) reported a pKa of 4.5.
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Studies assessing monensin sodium adsorption/desorption and biodegradation in soil were assessed
by the FEEDAP Panel in its opinion on the safety and efﬁcacy of Monimax® for turkeys (EFSA FEEDAP
Panel, 2017); the same conclusions on the fate and behaviour of monensin sodium can be retained for
the current assessment: ‘A Koc of 74.1 L/kg and a DT50 of 2.5 days at 20°C will be used for the
assessment’.
Predicted environmental concentrations (PECs)
The methodology for the calculation of the maximum predicted environmental concentrations
(PECs) in soil, groundwater, surface water and sediment are described in the technical guidance for
assessing the safety of feed additives for the environment (EFSA, 2008a).
The input values used for monensin A sodium were: 50 mg/kg broiler feed, molecular weight
693.8, vapour pressure 3 9 1028 Pa, solubility 8.78 mg/L, DT50 2.5 days and Koc 74.1 L/kg. The
calculated values are given in Table 7.
The Phase I PEC trigger values are exceeded, therefore a Phase II assessment is considered necessary.
3.2.4.2. Phase II
Exposure assessment
PECs calculation reﬁned in Phase II
PECsoil reﬁned for metabolism
In a former assessment of the environmental impact of monensin from Coxidin® (EFSA FEEDAP
Panel, 2011a), the FEEDAP Panel considered that about 20% of the monensin sodium ingested by
chickens was excreted unchanged. No information was given on the mode of administration of labelled
monensin (single or multidose). In a newly submitted study (see Section 3.2.2.1),30 14C-monensin was
administered for eight consecutive days at the same time as nicarbazin in order to take account of an
eventual interaction of both compounds. About 30% of the ingested monensin sodium was excreted
unchanged, numerous metabolites representing each < 10%. As these experimental conditions mimic
the practical use of Monimax®, the FEEDAP Panel considered that about 30% of the monensin
ingested by chickens was excreted unchanged.
Assuming that the ionophoric activity of monensin sodium and its metabolites in chicken excreta
will not exceed in total 30% of the orally administered dose, the reﬁned dose used for PEC calculations
was 50 9 0.3 = 15 mg/kg feed. The reﬁned PECsoil, PECgroundwater, PECsurfacewater and PECsediment are
reported in Table 8.
Table 6: Physico-chemical properties of monensin sodium
Property Value Unit
Octanol/water partition coefﬁcient (log Kow)
(1) 4.48 (pH 5.2–5.7, 25°C)
3.82 (pH 7, 25°C)
3.82 (pH 10, 25°C)
–
Water solubility (20°C)(2) 8.78 mg/L
Dissociation constant (pKa) 4.5 –
Vapour pressure(3) 3.03 9 1028 Pa
(1): Technical dossier/Supplementary information June 2015/Annex 4.
(2): Technical dossier/Supplementary information June 2015/Annex 27.
(3): EPI Suite, 2015.
Table 7: Initial predicted environmental concentration (PECs) of monensin sodium, in soil (lg/kg),
groundwater (lg/L), surface water (lg/L) and sediment (lg/kg dry weight)
Compartment PEC
Soil 260
Ground water 182
Surface water 61
Sediment 322
30 Technical dossier/Supplementary information June 2015/Annex 15.
Monimax® for chickens for fattening and chickens reared for laying
www.efsa.europa.eu/efsajournal 15 EFSA Journal 2018;16(11):5459
When the PECgroundwater is set equal to the concentration in pore water based on a worst-case
assumption (the total residue approach), the concentration exceeds the trigger value of 0.1 lg/L
identiﬁed by the EU as quality standard.31
PECgroundwater reﬁned with FOCUS
Leaching of monensin to groundwater was simulated using the FOCUS recommended leaching
model PEARL (FOCUS Version 4.4.3) (EFSA, 2008c). The calculated groundwater concentrations for the
scenarios Jokioinen and Piacenza were below 0.001 lg/L.
PECsurface water and PECsediment reﬁned with FOCUS
Concentrations in surface waters for monensin were assessed using the FOCUS Step 3 surface
water assessment approach. The FOCUS recommended surface water models PRZM_SW, MACRO and
TOXSWA were used (EFSA, 2008c). Generally, run-off was calculated from a soil receiving 0.234 kg
monensin/ha which was homogeneously distributed into a 20-cm deep layer. In the sensitive R1-
stream run-off scenario from FOCUS 4.4.3 using SPIN 2.2, the global maximum PECsurface water was
0.69 lg/L. The PECsediment value was 0.11 lg/kg dry weight.
Conclusions on PEC used for calculation
The following values are used for the assessment: PECsoil of 78 lg/kg, PECsurface water of 0.69 lg/L
and PECsediment 0.11 lg/kg dry weight.
Ecotoxicity studies
The effects of monensin sodium on the aquatic, terrestrial and sediment compartments were
studied in a number of ecotoxicity studies already assessed in the FEEDAP opinion on the safety and
efﬁcacy of Monimax® for turkeys (EFSA FEEDAP Panel, 2017). The same conclusions can be retained
for the current assessment:
‘For the terrestrial compartment, data are available for micro-organisms, earthworms and plants.
The lowest toxicity value for the terrestrial compartment of EC50 4 mg monensin/kg was found for
plant species Sinapis alba.
For the aquatic compartment, data are available for algae, aquatic invertebrates, ﬁsh and
information from public literature on the effect of monensin sodium on zooplankton. The ErC50 and
ErC10 used in the assessment are 3.3 mg/L and 0.91 mg/L for algae, respectively. The 48h EC50 for
immobilisation of daphnids was determined to be 7.29 mg monensin sodium/L and the 96h LC50 for
ﬁsh was 1.88 mg monensin sodium/L. The NOEL from the microcosmos study on zooplankton of 0.05
mg monensin sodium/L is as well used in the assessment.
Ecotoxicological data for sediment-dwelling invertebrates are provided for the sediment
compartment. The NOEC was determined as 5.0 mg monensin sodium/kg sediment (dry weight)’.
Table 8: Reﬁned predicted environmental concentrations (PECs) of monensin sodium, in soil (lg/
kg), groundwater (lg/L), surface water (lg/L) and sediment (lg/kg dry weight)
Input Value
Dose (mg/kg feed) 15
Molecular weight 693.8
Vapour pressure (Pa) (at 25°C) 3 9 1028
Solubility (mg/L) 8.78
Koc (L/kg) 74.1
DT50 in soil at 20°C (days) 2.5
Output
Application rate kg/ha 0.234
PECsoil 78
PECgroundwater 55
PECsurface water 18
PECsediment 97
31 Directive 2006/118/EC of the European Parliament and of the Council of 12 December 2006 on the protection of groundwater
against pollution and deterioration. OJ L 372, 27.12.2006, p. 19.
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Risk characterisation
The risk characterisation ratios for terrestrial, freshwater and sediment compartments are reported
in Tables 9, 10 and 11, respectively.
The previous risk characterisation for the terrestrial compartment (EFSA, 2005; EFSA FEEDAP Panel,
2011a) for plants was based on a NOEC. A re-assessment of the original data indicated a large
variability between the individual data and showed that the NOEC values would be less reliable than
the EC50 values. Therefore, the FEEDAP Panel decided to base the risk characterisation of plants on
the EC50 values.
Bioaccumulation
No data on bioaccumulation on monensin sodium were submitted. The log Kow at pH 7 is 3.2 and
there is evidence that monensin is degraded in the animal body (see Section 3.2.2.1). Therefore, a risk
for bioaccumulation is unlikely.
Table 9: Risk characterisation of monensin (PEC/PNEC ratio) for terrestrial compartment
Taxa PECsoil (lg/kg) EC50/LC50 (mg/kg) AF PNEC (lg/kg) PEC/PNEC
Earthworm 78 108.8(1) 100 1,088 0.07
Plants 4.0(2) 100 40 1.95
AF: assessment factor.
(1): LC50.
(2): EC50.
Table 10: Risk characterisation (PEC/PNEC ratio) for freshwater compartment
Taxa
PECsurfacewater FOCUS
(lg/L)
ErC50/ErC10/NOEL
(mg/L)
AF
PNEC
(lg/kg)
PEC/PNEC
Algae
Selenastrum capricornutum
0.69
3.3(1)
0.91(2)
1,000
1,000
3.41
0.91
0.2
0.76
Aquatic invertebrates
Daphnia magna
7.29(3) 1,000 7.3 0.09
Fish
Brachydanio rerio
1.83(4) 1,000 1.83 0.38
Microcosm 0.69 0.05(5) 10 5 0.14
AF: assessment factor.
(1): ErC50.
(2): ErC10.
(3): 48-h EC50.
(4): 96-h LC50.
(5): NOEL.
Table 11: Risk characterisation (PEC/PNEC ratio) for sediment
Taxa
PECsediment
(lg/kg dry weight)
NOEC
(mg/kg)
AF
PNEC
(lg/kg)
PEC/PNEC
Sediment-dwelling
invertebrates
Chironomus riparius
0.11 5.0 10 0.485 0.23
AF: assessment factor.
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NICARBAZIN (DNC and HDP)
3.2.4.3. Phase I
Physico-chemical properties
The physical–chemical properties of DNC and HDP are summarised in Tables 12 and 13.
Studies assessing DNC and HDP adsorption/desorption and biodegradation in soil were assessed by
the FEEDAP Panel in its opinion on the safety and efﬁcacy of Monimax® for turkeys (EFSA FEEDAP
Panel, 2017); the same conclusions on the fate and behaviour of DNC and HDP can be retained for the
current assessment: ‘For DNC, a Koc of 74,128 and a DT50 of 1,191 days will be used for the
assessment; for HDP a Koc of 102 and a DT50 of 2.3 days will be used for the assessment’.
Predicted environmental concentrations (PECs)
The input values for DNC used were: 35.44 mg/kg broiler feed, molecular weight 302.24, vapour
pressure 3.1 9 1010 Pa, solubility 0.0209 mg/L, DT50 1,191 days and Koc 74,128 L/kg. The input
values for HDP used were: HDP concentration in turkey feed 14.56 mg/kg, molecular weight 124.14,
vapour pressure 9.084 9 106 Pa, solubility 65,400 mg/L, DT50 4.9 days and Koc 102 L/kg.
The calculated PEC initial values for both DNC and HDP are given in Table 14.
Table 12: Physical–chemical properties of DNC
Property Value Unit
Octanol/water partition coefﬁcient (log Kow)(1) 3.25 (pH 5)
3.21 (pH 7)
3.23 (pH 9)
–
Water solubility (20°C)(1) 0.0209 (pH 5–9, 20  0.5°C) mg/L
Dissociation constant (pKa)(2) 12.44  0.70(3) –
Vapour pressure(1) 3.1 9 1010 Pa
(1): Technical dossier/Supplementary information June 2015/Annex 9.
(2): Technical dossier/Supplementary information June 2015/Annex 3.
(3): Estimated value since the substance exhibits insufﬁcient water solubility and ultraviolet-visible absorptivity to enable
experimental determination.
Table 13: Physical–chemical properties of HDP
Property Value Unit
Octanol/water partition coefﬁcient (log Kow)(1) 0.9546 (pH 5)
0.9232 (pH 7)
0.9528 (pH 9)
–
Water solubility (20°C)(1) 66,740 (pH 5, 20°C)
65,400 (pH 7, 20°C)
70,290 (pH 9, 20°C)
mg/L
Dissociation constant (pKa)(1) 3.75 (25°C) –
Vapour pressure(1) 9.084 9 106 (20°C)
1.834 x 105 (25°C)
Pa
(1): Technical dossier/Supplementary information June 2015/Annex 8.
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The Phase I PEC trigger values are exceeded, therefore a Phase II assessment is considered
necessary.
3.2.4.4. Phase II
Exposure assessment
PECs calculation reﬁned in Phase II
DNC – reﬁnement of PECsoil for persistent compounds
The DT90 for DNC in all four soils was determined to be greater than 1 year, therefore the PECs
reﬁned at steady state was calculated (EFSA, 2008a). The results are provided in Table 15.
DNC – PECsurface water PECsediment reﬁned with FOCUS
Concentrations in surface waters for DNC were assessed using the FOCUS Step 3 surface water
assessment approach. The FOCUS recommended surface water models PRZM_SW, MACRO and
TOXSWA were used.32 A FOCUS PRZM calculation was performed with an application rate of 552 g/ha,
a Koc of 74,128 L/kg and a DT50 of 562 days at 20°C. According to the manual, the drainage scenarios
D3 and D5 were selected together with the run-off scenarios R1 and R3. For the run-off scenarios a
homogeneous distribution of the DNC in 20 cm soil layer was assumed.
After 20 years, 3,600 g/ha was accumulated in the soil. This corresponds to 1,200 lg DNC/kg soil.
Due to the high Koc, there was no drainage of DNC to groundwater, surface water or sediment.
The run-off scenarios revealed a different picture. The R3 stream scenario indicated a maximum
time weighted average exposure concentration of DNC in surface water to be 0.027 lg/L in the ﬁrst
year. The corresponding sediment concentration was 54 lg/kg sediment. Since the run-off will be
3,600/552 = 6.5 times higher after 20 years, the surface water concentration will be
6.5 x 0.027 = 0.18 lg/L. The sediment concentration can exceed 6.5 9 54=351 lg/kg since DNC
might accumulate over the years in sediment. Nitroaromatic compounds can be reduced in sediment
to the corresponding anilines (van Beelen and Burris, 1995). Nevertheless, no data on the
Table 15: Reﬁned plateau predicted environmental concentrations (PECs) of DNC in soil (lg/kg),
groundwater (lg/L), surface water (lg/L), and sediment (lg/kg dry weight)
Compartment PECplateau
Soil 962
Ground water 0.74
Surface water 0.24
Sediment 909
Table 14: Initial predicted environmental concentrations (PECs) of DNC and HDP (lg/kg), in soil
(lg/kg), groundwater (lg/L), surface water (lg/L) and sediment (lg/kg dry weight)
Input
Value
DNC HDP
Dose (mg/kg feed) 35.44 14.56
Molecular weight 35.44 124.14
Vapour Pressure (Pa) (at 25°C) 3E-10 9E-6
Solubility (mg/L) 0.029 65,400
Koc (L/kg) 74,128 102
DT50 in soil at 12°C (days) 1,191 4.9
Output
PECsoil 184 76
PECgroundwater 0.141 40
PECsurfacewater 0.047 13
PECsediment 174 88
32 Technical dossier/Supplementary information February 2017/Annex 27.
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transformation of DNC in sediment were provided by the applicant. Especially in aerobic sediments,
there might be a continuous increase in DNC concentrations over the years.
Conclusions on PEC used for calculation
The following values are used for the assessment: for DNC a PECsoil of 1,200 lg/kg, a PECsurface water
of 0.18 lg/L and a PECsediment of > 351 lg/kg; for HDP a PECsoil of 76 lg/kg, PECsurface water of 13 lg/L
and PECsediment of 88 lg/kg.
Ecotoxicity studies
The effects of DNC and HDP on the aquatic, terrestrial and sediment compartments were studied in
a number of ecotoxicity studies already assessed in the FEEDAP opinion on the safety and efﬁcacy of
Monimax® for turkeys (EFSA FEEDAP Panel, 2017). The same conclusions can be retained for the
current assessment:
‘For the terrestrial compartment, data were provided for micro-organisms, earthworms and plants.
For the effect of DNC and HDP on the reproduction of earthworms, the NOEC was set on 300 and
123.46 mg/kg (dry weight), respectively. In two of six tested plant species, a statistically signiﬁcant
effect of the equimolar mixture of DNC and HDP was observed, however the effect concentration could
not be calculated. The FEEDAP Panel calculated the effect concentration based on information
provided in the test report. Assuming the worst case, the EC50 for plants is set to 102 mg/kg and 248
mg/kg of HDP and DNC, respectively.
For the aquatic compartment, data for DNC are available for acute and chronic effect on algae,
aquatic invertebrates and on acute toxic effects on ﬁsh. No effect of DNC could be observed in any of
performed tests, thus, the applicant proposes the lowest concentration tested as the NOEC value. The
DNC NOEC for algae is set to 10.13 lg/L. The 21-day NOEC for reproduction of daphnids was
determined to be 4.51 lg/L. The 96 h LC50 in ﬁsh was determined to be > 5.4 lg/L. Data for the toxic
effect of HDP on the aquatic compartment was studied in tests of acute and long term effect on algae
and acute effect on daphnids and ﬁsh resulting in NOEC value of 101.5 mg/L for algae. The LC50 and
EC50 for ﬁsh and immobilisation for Daphnia were determined to be > 100 mg/L, respectively. Data on
the effect of DNC and HDP on cyanobacteria are considered as supportive information.
Ecotoxicological data for the DNC and HDP for sediment-dwelling invertebrates are provided for the
sediment compartment. The NOEC for DNC and HDP were determined as 241.1 and 556.7 mg/kg
sediment (dry weight), respectively’.
Risk characterisation (PEC/PNEC ratio) for DNC and HDP
The risk characterisation ratios for terrestrial, freshwater and sediment compartments are reported
in Tables 16–20.
Table 16: Risk characterisation (PEC/PNEC ratio) for DNC and for HDP for the terrestrial
compartment
Taxa PECsoil (lg/kg) EC50/NOEC (mg/kg) AF PNEC (lg/kg) PEC/PNEC
DNC Earthworm 1,200 300(1) 10 30,000 0.032
Plants 248(2) 100 2,480 0.5
HDP Earthworm
76
123.46(1) 10 12,346 0.006
Plants 102(2) 100 1,020 0.07
AF: assessment factor.
(1): NOEC.
(2): EC50.
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According to the FEEDAP guidance on the environmental risk assessment for feed additives (EFSA,
2008c), two chronic tests on the aquatic compartment would allow a risk assessment of this
compartment. Chronic tests with DNC were provided for algae and aquatic invertebrates, with HDP
only for algae.
Bioaccumulation
No data on bioaccumulation have been submitted. The log Kow for DNC is > 3 for HDP < 3. The
high persistence and hydrophobicity of DNC indicate that there might be a risk for bioaccumulation.
Table 17: Risk characterisation (PEC/PNEC ratio) for the freshwater compartment for the DNC
Taxa
PECsurfacewater
(lg/L)
LC50/NOEC
(lg/L)
AF
PNEC
(lg/kg)
PEC/PNEC
Algae
Selenastrum subspicatus
0.18
10.13(1) 50 0.20 0.9
Aquatic invertebrates
Daphnia magna
4.51(1) 50 0.09 2
Fish
Brachydanio rerio
> 5.4(2) / /
AF: assessment factor.
(1): NOEC.
(2): 96-h LC50.
Table 18: Risk characterisation (PEC/PNEC ratio) for the freshwater compartment for the HDP
Taxa
PECsurfacewater
(lg/L)
EC50/LC50/NOEC
(mg/L)
AF
PNEC
(lg/kg)
PEC/PNEC
Algae
Selenastrum subspicatus
13
101.5(1) 1,000 101.5 0.13
Aquatic invertebrates
Daphnia magna
> 100 mg/L(2) /
Fish
Brachydanio rerio
> 100 mg/L(3) /
AF: assessment factor.
(1): NOEC.
(2): EC50.
(3): LC50.
Table 19: Risk characterisation (PEC/PNEC ratio) for sediment for the DNC
Taxa
PECsediment
(lg/kg)
NOEC
(mg/kg)
AF
PNEC
(lg/kg)
PEC/PNEC
Sediment-dwelling invertebrates
Chironomus riparius
> 351 241 10 24,100 /
AF: assessment factor.
Table 20: Risk characterisation (PEC/PNEC ratio) for sediment for the HDP
Taxa
PECsediment
(lg/kg)
NOEC
(mg/kg)
AF
PNEC
(lg/kg)
PEC/PNEC
Sediment-dwelling invertebrates
Chironomus riparius
88 556.7 10 55,670 0.001
AF: assessment factor.
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3.2.4.5. Conclusions on safety for the environment
The use of monensin sodium from Monimax® in complete feed for chickens for fattening does not
pose a risk for the aquatic compartment and sediment, while a risk cannot be excluded for the
terrestrial compartment based on the results of an ecotoxicity test on plants. The bioaccumulation
potential of monensin in the environment is low.
A ﬁnal conclusion on the risk resulting from the use of nicarbazin from Monimax® in chickens for
fattening cannot be made for the following reasons: (i) DNC reﬁned PECs showed uncertainties linked
to the very high persistence of the compound, (ii) DNC might accumulate in the sediment
compartment, and (iii) DNC can potentially bioaccumulate and may cause secondary poisoning. The
PEC/PNEC ratios indicate a risk for daphnids but no adverse effect were seen at the concentration
tested. This adds further uncertainty to the risk assessment of DNC in the aquatic compartment. No
concerns would arise for the HDP moiety of nicarbazin excreted from chickens fed Monimax®.
The potential of DNC to accumulate in soil over the years should be investigated by monitoring in a
ﬁeld study.
In summary, based on the available data, the FEEDAP Panel cannot conclude on the safety of Monimax®
for the environmental risk assessment. This conclusion is extended to chickens reared for laying.
3.3. Efﬁcacy
Efﬁcacy data for coccidiostats (following Art. 4 of Reg. (EC) No 1831/2003) should derive from
three types of target animal experiments (Reg. (EC) No 429/2008): (a) dose–titration studies (b)
natural/artiﬁcial infection to simulate use conditions (e.g., ﬂoor pen studies with poultry), at least one
of the locations should be in the EU, and (c) actual use conditions in ﬁeld trials; all should be done in
the EU within the last 5 years. Anticoccidial sensitivity tests (AST) could replace ﬁeld trials provided
they follow the criteria mentioned in the guidance document on coccidiostats and histomonostats
(EFSA FEEDAP Panel, 2011b).33
3.3.1. Efﬁcacy studies in chickens for fattening
The applicant submitted two dose–titration studies, six ﬂoor pen studies, one ﬁeld trial and four
ASTs performed with chickens for fattening.
3.3.1.1. Dose–titration studies in chickens for fattening
The applicant submitted two dose–titration studies made under controlled conditions in chickens for
fattening artiﬁcially infected with mixed Eimeria spp. The efﬁcacy of Monimax® was also compared
with that of the single anticoccidial components of Monimax®, monensin sodium (in both studies) and
nicarbazin (in one study). In both studies, oocyst excretion and intestinal lesion scores were
determined as speciﬁc endpoints in addition to the zootechnical parameters. An ANOVA was performed
with the data; group means were compared with the Tukey’s test.
In the ﬁrst dose–titration study, a total of 504 one-day-old male and female chickens for fattening
(Ross) were distributed to seven treatment groups (12 pens per treatment, six chickens per pen); an
uninfected untreated control group (UUC) was compared with an infected untreated control (IUC) and
ﬁve infected treated groups (IT).34 The treatments were 100 mg monensin/kg feed (IT-Mo), 125 mg
nicarbazin/kg (IT-Ni) and 30 + 30 (IT-MoNi 30), 40 + 40 (IT-MoNi 40) and 50 + 50 (IT-MoNi 50) mg
monensin + nicarbazin/kg feed; dosage was analytically conﬁrmed. On day 16, the groups IUC and IT
were inoculated with about 100,000 Eimeria oocysts per chicken via water for drinking. The anticoccidial
dietary treatment was provided from day 1 until day 35 (study completion). At the end of the study, no
differences in body weight were observed. Faecal oocyst counts per gram (OPG) in the infected groups
did mostly not differ signiﬁcantly; an interpretation of these data is limited due to the high variability
between pens. Among infected groups, lesion scores in the different intestinal segments showed best
values in the IT-MoNi 50 group followed by the IT-MoNi 40, IT-Mo and IT-Ni; however, none of the scores
was signiﬁcantly different to the IUC group. No lesions were seen in the UUC group.
33 The FEEDAP Panel stated in its guidance for the preparation of dossiers for coccidiostats and histomonostats (EFSA FEEDAP
Panel, 2011a,b,c) that studies with artiﬁcial infection would be preferred over ﬁeld trials due to their inherent weaknesses.
These short term studies should use ﬁeld strains of Eimeria, recently conﬁrmed as pathogenic/resistant by a sensitivity test or
recognised problems in the poultry operation (conﬁrmed by veterinary certiﬁcate). The Eimeria ﬁeld strains should ideally
undergo one, but in any case not more than two passage(s) before use in such trials.
34 Technical dossier/Section IV/Annex IV.1.
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In the second dose–titration study, a total of 210 one-day-old chickens for fattening (Ross) was
distributed to seven treatment groups (six pens per treatment, ﬁve chickens per pen).35 The original
study design could not be followed due to an error in feed attribution to the groups. In fact, there was
an IUC group with 12 pens (2 9 6) and ﬁve treated groups with six pens each: an uninfected treated
group (UTC-Ni) receiving 125 mg nicarbazin/kg feed and four infected treated groups receiving 100
mg monensin/kg feed (IT-Mo), 40 + 40 (IT-MoNi 40), 50 + 50 (IT-MoNi 50) and 60 + 60 (IT-MoNi 60)
mg monensin + nicarbazin/kg feed. On day 18, 180 birds were inoculated with about 500,000
sporulated oocysts of Eimeria spp. The anticoccidial dietary treatments were provided from day 15
until day 30 (study completion). OPG values measured on day 23 and 30 showed a reduction in oocyst
excretion in the IT groups compared to the IUC group. The difference was found to be signiﬁcant only
on day 23. There was no difference among the treatment groups. Lower lesion scores were observed
in IT groups with respect to the IUC group but statistical signiﬁcance was reached only in group IT-
MoNi 60. For the total duration of the study, no difference was observed among the infected groups in
the performance of the birds. In the ﬁrst week after inoculation, average daily weight gain in the IT
groups was signiﬁcantly higher than in the IUC.
3.3.1.2. Floor pen studies in chickens for fattening
Three ﬂoor pen studies in chickens for fattening, conducted in 2011, were submitted.36 In each
study, male chickens (Ross 308) were penned and distributed into three treatment groups: an UUC
group, an IUC group and an IT group. The IT group received feed containing 40 mg monensin and 40
mg nicarbazin/kg feed. In the infected groups, individually tagged seeder birds (10 out of 60 per pen
in trial 1, 10 out of 33 per pen in trial 2 and 8 out of 37 in trial 3) were inoculated with recent ﬁeld
isolates of pathogenic Eimeria species. The same number of animals were sham-inoculated (water
only) in the UUC group. Mortality could not be considered as an endpoint indicating coccidiostatic
efﬁcacy since it was low in two studies. In one study the mortality was affected by oocyst inoculation
but no improvement was seen due to the treatment. The Eimeria species speciﬁc lesion scores were
determined in three ﬂoor pen studies at three different time points (resulting in a total of 27 data
sets). The seeder bird model used in the ﬂoor pen studies did not appear very sensitive in indicating a
disease protecting effect of the coccidiostat in all birds used (the severity of intestinal lesions in
contact birds was affected by the infection only in 2 out of 18 data sets while in seeder birds in 6 out
of 9 data sets). The coccidiostat reduced signiﬁcantly the severity of intestinal lesions only in one of 18
cases in contact birds and in one of 9 cases in seeder birds.
Treatment with Monimax® did not signiﬁcantly reduce oocyst excretion in the three ﬂoor pen
studies measured at three time points for six different Eimeria species each.
Feed intake and body weight gain of birds in the ﬂoor pen studies were signiﬁcantly higher for the
infected treated groups compared to the infected non treated birds in the ﬂoor pen studies. However, in
the view of the FEEDAP Panel, these observations could not be used to derive a coccidiostatic effect, since
none of the speciﬁc endpoints (mortality, oocyst excretion and intestinal lesions) showed such effect.
Three additional ﬂoor pen studies, conducted in 2018, were submitted.37 The ﬁrst two studies were
conducted in the same research institute, at the same time, with the same feed, and used the same
UUC group. Therefore, they would not be considered as independent studies. In general, three
independent studies are needed to provide evidence of efﬁcacy, particularly under the different
conditions of use (e.g. place, feed and animals). These general criteria were established for all feed
additives of which the effect is on the composition or utilisation of feed (EFSA FEEDAP Panel, 2018).
Coccidiostats act on Eimeria spp. irrespectively of the composition of the feed and are not considered
to modulate feed utilisation. Consequently, the inoculum with sporulated oocysts is considered the
most critical factor in studies with artiﬁcial infection. In these studies, efﬁcacy of the coccidiostat
should be assessed by comparing the effect of Eimeria inocula observed in the IT group against the
IUC. The UUC group (common control in these studies) is used only to verify the growth of the
animals under farming conditions similar to those in ﬁeld. The statistical approach applied in the two
studies reﬂected this concept and compared the IUC against IT. Taking into account the above and the
fact that in the two studies inocula with different geographical origin were used, the Panel considers
35 Technical dossier/Section IV/Annex IV.2.
36 Trial 1: Technical dossier/Section IV/Annex IV.3. Trial 2: Technical dossier/Section IV/Annex IV.4. and Trial 3: Technical
dossier/Section IV/Annex IV.5.
37 Trial 1: Technical dossier/Supplementary information May 2018/Annex 1 - R-H-2017-132. Trial 2: Technical dossier/Supplementary
information May 2018/Annex 2 - R-H-2017-133. and Trial 3: Technical dossier/Supplementary information May 2018/Annex 3 - R-
H-2017-138.
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that the two trials could be used to assess independently the effect of the additive against different
Eimeria inocula. Therefore, the two studies could be considered as separate studies.
In each study, male chickens (Ross 308) were penned and distributed into three treatment groups:
a UUC, an IUC and an IT group. The IT group received feed containing 40 mg monensin sodium and
40 mg nicarbazin/kg feed; the doses were analytically conﬁrmed. The duration of the studies was 35
days and the experimental diets were fed from day 11 (trials 1 and 2) or from day 12 (trial 3). All birds
in the IUC and IT groups were inoculated with recent ﬁeld isolates of pathogenic Eimeria species two
days after administration of the experimental diet (see Table 21). In the UUC group of trial 3, all birds
were sham-inoculated with drinking water. In trials 1 and 2, the doses of inocula were chosen to give
about 25% drop in weight gain of the IUC group compared to UUC. In trial 3, the dose of the
inoculum was intended to cause weight gain depression of about 15% and lesion scores (LS) of
approximately 2 for E. acervulina and E. tenella at 6–7 days after inoculation. Animal health and
mortality were monitored daily. Feed intake and body weight of the animals were measured, feed to
gain ratio was calculated. Samples of excreta were analysed for oocyst excretion (results were
expressed as OPG). Intestinal lesions were scored using the method of Johnson and Reid (1970) 1, 2
and 3 weeks post inoculation on eight birds per pen in trial 1 and 2 and ten birds in trial 3.
In trials 1 and 2, a two-sided signiﬁcance level a = 0.05 was used to detect differences between IT
and IUC groups. Lesion scoring data as well as mortality and morbidity data were assessed using
categorical data analysis (v2 from Kruskal–Wallis test). For statistical analysis of continuous variables, a
randomised complete block design was used (ANOVA with treatment as ﬁxed effects and block as
random effect). If data could be approximated to a normal distribution, they were analyzed in the
same manner as the continuous variables.
In trial 3, performance data and OPG were analysed on a pen basis using a linear regression model
(ANOVA) with treatment group as ﬁxed effect. After assessing the statistical signiﬁcance of the ﬁxed
effect considered (p ≤ 0.05), the difference between the treatment groups was assessed by Bonferroni
post hoc test (p ≤ 0.05). Data on intestinal lesion scores were analysed at bird level using a linear
mixed regression model (ANOVA) with treatment group and day after inoculation as ﬁxed effects and
pen as random effect. After assessing the statistical signiﬁcance of the ﬁxed effects considered
Table 21: Experimental design of three ﬂoor pen studies with chickens for fattening using
Monimax®
Trial
Replicates
per
treatment
(Birds per
replicate)
Inoculum characteristics
Feed analysis
(mg/kg feed)(1)
Month/year
and country
of isolation
Intended dose per bird
Day and mode
of inoculation
Monensin Nicarbazin
1 5 (47) 12/2017 Galicia
(NW Spain)
50,000 E. acervulina Day 13 orally
via feed
< 0.5/41/43 < 1/43/42
15,000 E. tenella
20,000 E. maxima
10,000 E. brunetti
25,000 E. mitis
10,000 E. necatrix
2 5 (47) 12/2017
Zaragoza
(NE Spain)
75,000 E. acervulina Day 13 orally
via feed
< 0.5/41/43 < 1/43/42
20,000 E. tenella
30,000 E. maxima
30,000 E. mitis
15,000 E. necatrix
20,000 E. brunetti
3 8 (50) 2017
Europe
105,000 E. acervulina Day 14
via syringe
< 0.5/45 < 1/46
13,000 E. tenella
6,000 E. maxima
(1): In trial, 1 and 2, birds received starter diet (crumbles) from day 0 to 11 free of coccidiostat, grower diet (pelleted) from day
11 to 24 and ﬁnisher diet (pelleted) from day 24 to 35. In trial 3 birds received starter diet (pelleted) from day 0 to 12 free
of coccidiostat and grower diet (pelleted) from day 12 to 35.
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(p ≤ 0.05), the difference between the treatment groups within the same day was assessed by a
pairwise comparison with Bonferroni adjustment for multiple comparisons (p ≤ 0.05).
Mortality by coccidiosis after inoculation was signiﬁcantly reduced by Monimax® treatment in trials
1 and 2. No such effect was seen in trial 3 (see Table 25).
Tables 22 and 23 show the results of intestinal lesion scoring. A signiﬁcant reduction of LS was
seen in birds of IT groups compared to the IUC groups of trials 1 and 2 at day 19 (6 days post
inoculation) in upper, middle and lower part of duodenum. A similar observation was made in trial 1 at
day 27 (14 days post inoculation) for the middle part of the duodenum and caeca. At 22 days post-
inoculation no lesions were found in any group.
In trial 3, scores were evaluated for Eimeria speciﬁc and total Eimeria lesions at days 21, 28 and 35
(7, 14 and 21 days post inoculation) (Table 23). A signiﬁcant reduction of E. acervulina and E. maxima
lesions was found 7 days post inoculation, of E. tenella 14 and 21 days post-inoculation. LS for
E. maxima was also signiﬁcantly lower 21 days post inoculation.
Results of oocyst excretion are summarised in Table 24. Oocyst excretion was signiﬁcantly reduced
in the IT group compared to the IUC group on days 21, 28 and 35 (7, 14 and 21 days post-
inoculation) in trials 1 and 2. In trial 3, the oocyst excretion was not signiﬁcantly affected.
Table 22: Results of lesion scoring in the different intestinal sections in trials 1 and 2(1)
6 days post inoculation 14 days post inoculation
Upper Middle Lower Caeca Upper Middle Lower Caeca
Trial 1
UUC 0 0 0 0 0 0 0 0.1
IUC 1.5 1.7 1.3 2.1 0.2 0.3 0.1 0.4
IT 1.0* 1.0* 0.4* 2.0 0.1 0.1* 0 0*
Trial 2
UUC 0 0 0 0 0 0 0 0.1
IUC 2.0 2.2 1.6 2.4 0 0 0 0
IT 1.0* 1.1* 0.5* 2.0 0.1 0.1 0 0.1
(1): For the upper (E. acervulina and E. mitis), middle (E. maxima and E. necatrix), lower (E. brunetti) and caecal (E. tenella)
intestinal sections.
*: IT signiﬁcantly different from IUC (p ≤ 0.05).
Table 23: Coccidiosis lesion scoring based on Eimeria species-speciﬁc lesions in trial 3(1)
7 days post inoculation 14 days post inoculation 21 days post inoculation
Acer Max Ten Total Acer Max Ten Total Acer Max Ten Total
UUC 0.18a 0.14a 0.03a 0.34a 0.36 0.13a 0a 0.49a 1.40a 0.78a 0.05a 2.23a
IUC 2.00b 0.70b 1.16b 3.86b 0.41 0.69b 1.04b 2.14b 0.44b 0.73a 0.40b 1.56b
IT 1.51c 0.39a 1.03b 2.93c 0.29 0.46b 0.30c 1.05a 0.18b 0.34b 0.04a 0.55c
a,b,c: Means in a column with different superscript are signiﬁcantly different (p ≤ 0.05).
(1): Eimeria acervulina (Acer), Eimeria tenella (Ten), Eimeria maxima (Max).
Monimax® for chickens for fattening and chickens reared for laying
www.efsa.europa.eu/efsajournal 25 EFSA Journal 2018;16(11):5459
Table 25 shows the performance parameters including mortality. Eimeria infection resulted in a
signiﬁcant reduction of ﬁnal body weight in trial 1. In trials 1 and 2, feed to gain ratio was signiﬁcantly
reduced in the IT group compared with IUC group. In trial 3, the ﬁnal body weight and daily weight
gain (days 12–35) was signiﬁcantly higher in IT group compared with IUC group.
3.3.1.3. Field trial in chickens for fattening
The applicant provided a trial carried out in 2012 under controlled ﬁeld conditions.38 A total of
135,400 one-day-old male chickens for fattening distributed in four houses were allocated to two
groups (representing two houses per group). The control group received in the ﬁrst three weeks of life
feed containing a combination of a polyether coccidiostat (50 mg/kg) and a synthetic coccidiostat (50
mg/kg). From the fourth week, birds received feed containing only the polyether coccidiostat (60 mg).
The treated group received feed containing Monimax® (40 mg monensin and 40 mg nicarbazin/kg
Table 24: Total oocyst counts per gram (OPG; geometric means) in ﬂoor pen trials
Days post inoculation(1) 6/7 14 21/22
Trial 1
UUC nd nd nd
IUC 214,000 72,400 2,243
IT 39,800* 2,240* nd*
Trial 2
UUC nd nd nd
IUC 251,000 66,100 1,740
IT 49,000* 513* nd*
Trial 3
UUC 130b 245b 121,080a
IUC 127,503a 6,311ab 9,775b
IT 81,950a 9,724a 2,892b
nd: not detected.
(1): 6/14/22 days in Trial 1 and 2; 7/14/21 days in trial 3.
*: IT signiﬁcantly different from IUC (p ≤ 0.05).
a,b: means with different letters in a column are signiﬁcantly different.
Table 25: Performance parameters and mortality of chickens for fattening in ﬂoor pen studies(1)
Feed intake
(g/day)
Body
weight (g)
Weight
gain (g/day)
Feed to
gain ratio
Mortality(2) (n)
Trial 1
UUC 105.3 2,729 76.7 1.37 0
IUC 99.3 2,528 70.9 1.40 100
IT 102.7 2,656 74.6 1.37* 11*
Trial 2
UUC 105.3 2,729 76.7 1.37 0
IUC 103.8 2,645 74.3 1.40 117
IT 101.8 2,621 73.6 1.38 24*
Trial 3
UUC 121.8 2,044ab 73.0a 1.67 0
IUC 118.6 1,960b 66.8b 1.78 1
IT 122.6 2,075a 72.3a 1.70 0
(1): Results of trial 1 and 2 refer to the study period from 0 to 35 days; results of trial 3 refer to the period days 12–35.
(2): Coccidiosis related mortality; total mortality was: Trial 1: IT 12, IUC 105; UUC 5 birds; Trial 2: UUC 5, IUC 118; IT 5 birds;
Trial 3: UUC 1, IUC 3; IT 4 birds.
*: IT signiﬁcantly different from IUC (p ≤ 0.05).
a,b: Means with different letters in a column are signiﬁcantly different.
38 Technical dossier/Section IV/Annex IV.8.
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feed). Study duration was 35 days followed by a 1-week withdrawal period. At the age of 33, 34 or 36
days, around 30% animals of all houses were moved out for slaughtering without individual
identiﬁcation. The same happened with the remaining animals at the age of 40, 41 or 42 days at the
end of the study. Body weight was measured weekly in 50 animals per house. Lesion scores were
examined four times in ten animals per house. The selection criteria of animals taken for body weight
and lesion score measurement were not described. Faecal samples to determine the OPG were taken
weekly in each house.
The FEEDAP Panel ﬁnally did not consider the results of the ﬁeld study, due to the following
weaknesses in study design and reporting. Sum of dead/culled birds and those slaughtered was not in
a constant relation to the initial number of birds. Body weight appeared to depend more on the house
than on the anticoccidial treatment. A sample size of 50 birds is considered too small to give a reliable
estimate of the body weight of more than 30,000 birds (no selection criteria described). It is also not
expected that ten birds out of more than 30,000 will allow an estimate on the prevalence of lesion
scores.
3.3.1.4. Anticoccidial sensitivity tests in chickens for fattening
Four ASTs performed in 2011 (AST-1 and AST-2) and 2014 (AST-3 and AST-4) were submitted.39
Each test was made with the groups UUC, IUC and IT, the latter receiving feed supplemented with
Monimax® at an intended concentration of 40 mg monensin and 40 mg nicarbazin/kg feed, dosage
was analytically conﬁrmed (see Table 26). The birds (Ross PM3 in AST-1 and Ross 308 in AST-2, AST-3
and AST-4) were randomly allocated to the groups. In three of the studies other anticoccidial additives
were also tested (seven in AST-1, ﬁve in AST-3 and AST-4). Birds were artiﬁcially infected with
sporulated oocysts from recent ﬁeld isolates. In AST-3, also a test with a historical isolate (AST-3h) vs
a recent isolate (AST-3r) was made. Animal health and mortality were monitored. Feed intake and
body weight of the animals were measured, feed to gain ratio was calculated. Samples of excreta were
analysed for oocyst excretion. Intestinal lesions were scored following the method of Johnson and Reid
(1970) (0 = no lesion, 1 = very mild, 2 = mild, 3 = moderate and 4 = severe).
The data were analysed by ANOVA. Group differences at p ≤ 0.05 level were checked by Newman–
Keuls test or LSD. In AST-2 AST-3 and AST-4 lesion scores were analysed by a non-parametric test.
Table 26: Experimental design of ASTs with chickens for fattening using Monimax®
Replicates
per
treatment
(Birds per
replicate)
Inoculum characteristics
Anticoccidial
treatment(1)
(days of life)
Feed analysis
monensin +
nicarbazin
(mg/kg feed)
Month/year
and country
of isolation
Intended dose per bird
Day of
inoculation
AST-1 3 (6) 8/2011
France
248,600 E. acervulina 15 13–22 38 + 36
21,600 E. brunetti
AST-2 7 (5) 2011
Netherlands
62,000 E. acervulina 14 11–24 34 + 33
29,000 E. tenella
11,000 E. maxima
5,000 E. mitis
10,000 E. praecox
AST-3h 6 (5) 1996/EU 96,120 E. acervulina 17 13–23 41 + 39
16,920 E. tenella
12,900 E. maxima
5,040 E. mitis
11,520 E. necatrix/
praecox
39 AST-1: Technical dossier/Section IV/Annex IV.6. AST-2: Technical dossier/Section IV/Annex IV.7. AST-3: Technical dossier/
Spontaneous Supplementray Information April 2017/2014-09 ﬁnal. AST-4: Technical dossier/Spontaneous Supplementray
Information April 2017/2014-06 ﬁnal.
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Table 27 summarises the results of the four ASTs, giving consideration to the different isolates
(historical and recent) used in AST-3.
Mortality was low in AST-2, AST-3 and AST-4 and not coccidiosis related. Increased mortality due to
coccidiosis was seen only in IUC of AST-1, 6 birds out of 18 died and 4 deaths were coccidiosis related.
Oocyst excretion 6–9 days after inoculation indicated successful Eimeria infection on days 14–18. No
OPG was found in the UUC of AST-1, AST-2 and AST-3, and only a small number in AST-4. These
ﬁndings support the validity of the ASTs. OPG was signiﬁcantly reduced by the Monimax® treatment
(comparison of IT vs IUC) in AST-2, AST-3h, AST-3r and AST-4, but not in AST-1. In AST-1 and AST-2,
a reduction of Eimeria spp. speciﬁc lesion scores by treatment (IT) was not observed. In contrast, the
total average lesion score reported in AST-3h, AST-3r and AST-4 showed a signiﬁcant reduction in the
IT groups (compared to IUC) down to the level of UUC.
The adverse effect of oocyst inoculation was seen by a signiﬁcant depression (IUC vs. UUC) of feed
intake in AST-1 and AST-3r and of daily body weight gain in AST-1, AST-3r and AST-4. A beneﬁcial
effect of the anticoccidial treatment (IT vs. IUC) was observed as a signiﬁcantly higher feed intake in
AST-1 and AST-3r, signiﬁcantly higher daily weight gain in AST-1, AST-3r and AST-4.
Replicates
per
treatment
(Birds per
replicate)
Inoculum characteristics
Anticoccidial
treatment(1)
(days of life)
Feed analysis
monensin +
nicarbazin
(mg/kg feed)
Month/year
and country
of isolation
Intended dose per bird
Day of
inoculation
AST-3r 6 (5) 3/2012
Belgium
133,200 E. acervulina
12,240 E. tenella
2,880 E. maxima
14,040 E. mitis
25,200 E. necatrix/
praecox
AST-4 6 (5) 2/2013
Belgium
85,600 E. acervulina 18 15–25 39 + 44
35,000 E. tenella
68,000 E. maxima
3,200 E. praecox
64,000 E. mitis
(1): Birds in the IT group were fed a basal diet supplemented with Monimax®. Animals in the control groups UUC and IUC
received the same basal diet without inclusion of the coccidiostat.
Table 27: Results of anticoccidial sensitivity tests in chickens
Daily
Feed
Intake
(g)
Body
weight
(g)
Daily
Weight
Gain
(g)
Feed to
gain
ratio
Mortality
(n)
Total
OPG
Mean lesion scores(1)
Acer Bru Ten Max
AST-1 D13-22 D22 D13-22 D13-22 Total D20-22 D22
UUC 107.2a 1,025.3a 59.5a 1.80c 0b 0b 0.0b 0.0b – –
IUC 79.3c 657.5c 19.2c 4.17a 6a 2.7 9 108a 2.7a 2.1a – –
IT 98.2b 857.1b 40.0b 2.47b 0b 3.7 9 108a 3.1a 2.0a – –
AST-2 D11-24 D24 D11-24 D11-24 Total D20 D20
UUC 81a 870a 47a 1.7b 0 0c 0.00b – 0.07a 0.86a
IUC 78a 840a 44a 1.8ab 1 1.2 9 106a 1.43a – 0.07a 0.79a
IT 82a 837a 44a 1.8a 0 5.4 9 105b 1.43a – 0.14a 0.57a
AST-3h D17-23 D23 D17-23 D17-23 Total D21-23 Mean lesion score D23
UUC 107a 1,167a 78a 1.38a 0 0c 0.7b
IUC 97a 1,088b 63b 1.64a 2 9.9 9 105a 3.1a
IT 112a 1,118ab 70ab 1.68a 3 4.8 9 103b 0.5b
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3.3.1.5. Synopsis of the efﬁcacy studies in chickens for fattening
The synopsis is based on three newly submitted ﬂoor pen studies and four anticoccidial sensitivity
tests performed with the lowest applied concentration of the coccidiostat Monimax® (40 mg monensin
and 40 mg nicarbazin/kg feed).
The treatment with Monimax ® signiﬁcantly reduced mortality in two ﬂoor pen studies and in one
AST. In all ﬂoor pen studies, the treatment signiﬁcantly reduced intestinal lesion scores. In two of
them, a signiﬁcantly lower oocyst excretion was observed. The zootechnical data demonstrated the
depressive effect of Eimeria invasion, the treatment resulted in one study in an improvement of feed
to gain ratio and in another study of ﬁnal body weight compared to the IUC.
In all four ASTs oocyst inoculation resulted in a signiﬁcant increase of intestinal lesions, two of them
showed a signiﬁcant reduction owing to the treatment with Monimax®. The ASTs showed a signiﬁcant
reduction of oocyst excretion by Monimax® in three of four tests. In three of four ASTs, the
anticoccidial efﬁcacy of Monimax® demonstrated by an improvement of coccidiosis-related speciﬁc
endpoints was further conﬁrmed by an improvement of body weight gain. In ASTs, performance data
are regarded as supportive considering the short duration of the test period (10–14 days) and the
small number of animals per group (18–35) and per replicate (5–6).
3.3.2. Conclusions on efﬁcacy studies
Based on ﬂoor pen studies and anticoccidial sensitivity tests, the FEEDAP Panel concludes that
Monimax® has the potential to control coccidiosis in chickens for fattening at a minimum concentration
of 40 mg monensin and 40 mg nicarbazin/kg complete feed. The conclusion is extended to chickens
reared for laying.
3.4. Post-market monitoring
Field monitoring of Eimeria spp. resistance in chickens for fattening and chickens reared for laying
to monensin sodium/nicarbazin should be undertaken, preferably during the latter part of the period of
authorisation.
The potential of DNC to accumulate in soil over the years should be investigated by monitoring and
a ﬁeld study.
3.4.1. Conclusions
Monimax® is considered safe for chickens for fattening at the highest use level of 50 mg monensin
and 50 mg nicarbazin/kg complete feed. The margin of safety is about 1.5. This conclusion is
extended to chickens reared for laying. The simultaneous use of Monimax® and certain antibiotic
drugs (i.e. tiamulin) is contraindicated. Monensin has a selective antimicrobial activity against Gram-
positive bacterial species while many Enterobacteriaceae are naturally resistant. Induction of cross-
resistance with clinically relevant antimicrobials or increased shedding of enteropathogenic bacteria are
not reported. Nicarbazin has no antimicrobial activity.
Daily
Feed
Intake
(g)
Body
weight
(g)
Daily
Weight
Gain
(g)
Feed to
gain
ratio
Mortality
(n)
Total
OPG
Mean lesion scores(1)
Acer Bru Ten Max
AST-3r D17-23 D23 D17-23 D17-23 Total D21-23 Mean lesion score D23
UUC 107ab 1,167a 78a 1.38b 0 0c 0.7b
IUC 95b 1,029b 51b 1.97a 1 4.4 9 106a 4.7a
IT 115a 1,225a 82a 1.41b 0 1.6 9 105b 0.7b
AST-4 D15-25 D25 D15-25 D15-25 Total D25 Mean lesion score D23-25
UUC 117.3a 1,281.0a 81.3a 1.30b 0 3.0 9 102c 0.56b
IUC 116.9a 1,033.9b 55.2b 1.92a 1 1.2 9 106a 3.72a
IT 124.4a 1,318.3a 83.1a 1.35b 0 1.2 9 105b 0.67b
(1): Eimeria acervulina (Acer), Eimeria brunetti (Bru), Eimeria tenella (Ten), Eimeria maxima (Max).
a,b,c: Means within a column within a study with different superscript are signiﬁcantly different (p ≤ 0.05).
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Monensin sodium is absorbed at a limited extent and excreted rapidly, it is extensively metabolised
and gives rise to demethylated, oxidised and decarboxylated metabolites. Nicarbazin, when ingested, is
rapidly split in its two components HDP and DNC which behave independently. Liver is the target
tissue. DNC residues decline rapidly from tissues following nicarbazin withdrawal. DNC appears as the
marker residue. HDP-related residues are much lower than those derived from DNC. For both
compounds of Monimax®, the metabolic pathways in the chicken are similar to those in the turkey and
rat. The potential interaction, if any, of monensin and nicarbazin has been taken into consideration.
The FEEDAP Panel concludes that the active substances in Monimax®, monensin sodium and
nicarbazin, do not represent a genotoxic risk. No safety concerns would arise from the nicarbazin
impurities PNA and M4NPC. Monensin sodium has no structural alert for carcinogenesis. Monensin
sodium is not a reproductive or developmental toxicant. The lowest NOEL identiﬁed in the
developmental study in rabbits is 0.3 mg monensin sodium/kg bw per day for maternal toxicity in
rabbits. The primary toxicity resulting from the oral use of nicarbazin is renal toxicity. The absence of
similar ﬁndings after treatment with DNC and HDP conﬁrms that this equimolar association of
compounds is better tolerated than nicarbazin at equivalent doses. The lowest NOAEL identiﬁed in a
52-week study in rat using DNC + HDP was 20 mg DNC + 8 mg HDP/kg bw per day based on the
absence of microcrystals in urine and related microscopic renal observations. No signiﬁcant interaction
between monensin sodium and nicarbazin is expected from toxicological studies.
The use of Monimax® at the highest proposed dose (50 + 50 mg monensin + nicarbazin/kg
complete feed) will not pose a risk to persons consuming animal products from treated chickens for
fattening. This conclusion is extended to chickens reared for laying up to 16 weeks of age. No safety
concern would arise from the impurity PNA if the maximum content in nicarbazin of 0.1% is respected.
The impurity M4NPC is considered safe for the consumer provided that a maximum concentration of
0.4% in nicarbazin is not exceeded. No withdrawal time is required for Monimax® in chickens for
fattening. Residue data comply with the established MRLs for monensin and DNC.
The monensin sodium contained in Monimax® presents a hazard by inhalation. Monimax® is not a
skin irritant; however, no data are available for the eye irritation potential of monensin. Monimax® may
also act as a dermal toxicant due to its monensin component. Monimax® is not a skin sensitiser.
The use of monensin sodium from Monimax® in complete feed for chickens for fattening does not
pose a risk for the aquatic compartment and sediment, while a risk cannot be excluded for the
terrestrial compartment. A ﬁnal conclusion on the risk resulting from the use of nicarbazin from
Monimax cannot be made because (i) DNC reﬁned PECs show uncertainties linked to the very high
persistence of the compound, (ii) DNC might accumulate in the sediment compartment, and (iii) DNC
can potentially bioaccumulate and may cause secondary poisoning. No concerns would arise for the
HDP moiety of nicarbazin excreted from chickens fed Monimax®. Based on the available data, the
FEEDAP Panel cannot conclude on the safety of Monimax for the environment.
Based on the submitted ﬂoor pen studies and anticoccidial sensitivity tests evaluated, the FEEDAP
Panel concludes that Monimax® has the potential to control coccidiosis in chickens for fattening at a
minimum concentration of 40 mg monensin and 40 mg nicarbazin/kg complete feed. The conclusion is
extended to chickens reared for laying.
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Huvepharma N.V.
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3) Monimax® for chickens for fattening and chickens reared for laying. Supplementary
information. June 2015. Submitted by Huvepharma N.V.
4) Monimax® for chickens for fattening and chickens reared for laying. Supplementary
information. October 2015. Submitted by Huvepharma N.V.
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8) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods of Analysis for Monimax®.
9) Comments from Member States.
Chronology
Date Event
26/7/2012 Dossier received by EFSA
29/8/2012 Reception mandate from the European Commission
31/1/2013 Application validated by EFSA – Start of the scientiﬁc assessment
13/3/2013 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: Methods of analysis
30/4/2013 Comments received from Member States
30/10/2014 Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives
3/6/2015 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
4/12/2015 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation, safety for target
species, safety for the consumer, safety for the user and efﬁcacy
3/2/2017 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
25/7/2017 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation, safety for target
species, safety for the consumer, safety for the user and efﬁcacy
26/10/2017 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
5/12/2017 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation, safety for target
species, safety for the consumer, safety for the user and efﬁcacy
3/05/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
2/10/2018 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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Abbreviations
ADI acceptable daily intake
ADME absorption, distribution, metabolism and excretion
AF assessment factor
ANOVA analysis of variance
AST anticoccidial sensitivity tests
bw body weight
CAS Chemical Abstracts Service
DITR Dietary intake of total residues
DNC dinitrocarbanilide
DT50 disappearance time 50 (the time within which the concentration of the test
substance is reduced by 50%)
DT90 disappearance time 90 (the time within which the concentration of the test
substance is reduced by 90%)
EC50 median effective concentration
ErC10 median effective concentration which results in a 10% reduction in growth rate
ErC50 median effective concentration which results in a 50% reduction in growth rate
EURL European Union Reference Laboratory
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
FOCUS FOrum for Co-ordination of pesticide fate models and their USe
GLP Good Laboratory Practice
HDP 2-hydroxy-4,6-dimethylpyrimidine
Koc adsorption or desorption coefﬁcient corrected for soil organic carbon content
LC50 median lethal concentration
LOD limit of detection
log Kow octanol/water partition coefﬁcient
LOQ limit of quantitation
M4NPC methyl(4-nitrophenyl) carbamate
MIC minimum inhibitory concentrations
MRC marker residue concentration
MRL maximum residue limit
NOAEL no observed adverse effect level
NOEC no observed effect concentration
NOEL no observed effect level
OECD Organisation for Economic Co-operation and Development
OPG oocysts per gram of excreta
PEC predicted environmental concentration
pKa dissociation constant
PNA p-nitroaniline
PNEC predicted no effect concentration
RMTR ratio marker to total residues
SCAN Scientiﬁc Committee on Animal Nutrition
SD standard deviation
TRC total residue concentration
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Method(s) of
Analysis for Monimax
In the current application authorisation is sought for Monimax®, under article 4(1), for the category
‘coccidiostats and histomonostats’, according to the classiﬁcation system of article 6 of Regulation (EC)
No 1831/2003. Authorisation is sought for chickens for fattening and chickens reared for laying.
Monimax® consists of 80 g/kg of monensin sodium and 80 g/kg of nicarbazin complemented by starch
for granulation, wheat meal and calcium carbonate.
Monimax® is intended to be incorporated in feedingstuffs through premixtures and it is not to be
mixed with other coccidiostats. For each of the active substances the Applicant proposes a ﬁnal
concentration in feedingstuffs ranging from 40 to 50 mg/kg. Furthermore, the Applicant proposed
maximum residue limits (MRLs) in skin/fat, muscle, liver and kidney. As these MRLs are not set up by
Commission Regulation (EC) No 37/2010, the correspondent methods of analysis have to be evaluated
by the EURL.
For the quantiﬁcation of monensin sodium in premixtures and feedingstuffs the Applicant submitted
the multi-analyte ring-trial validated method EN ISO 14183 based on High Performance Liquid
Chromatography with post-column derivatisation and VIS detection (HPLC-VIS). The Applicant applied
this method for the analysis of the feed additive and presented performance characteristics similar to
those reported for the EN ISO standard method. Based on the experimental evidence available the
EURL recommends for ofﬁcial control the HPLC with post-column derivatisation and VIS detection for
the quantiﬁcation of monensin sodium in the feed additive, premixtures and feedingstuffs.
For the quantiﬁcation of nicarbazin in premixtures and feedingstuffs the Applicant submitted the
ring-trial validated method EN ISO 15782 based on HPLC coupled with ultraviolet (UV) detection. A
similar method was used by the Applicant for the quantiﬁcation of nicarbazin in the feed additive.
Based on the performance characteristics presented the EURL recommends for ofﬁcial control the
HPLC method with UV detection for the quantiﬁcation of nicarbazin in the feed additive, premixtures
and feedingstuffs.
For the quantiﬁcation of monensin sodium and nicarbazin in target tissues (skin/fat, muscle, liver
and kidney) the Applicant submitted a single-laboratory and further veriﬁed method based on
reversed-phase high performance liquid chromatography coupled to a triple quadrupole mass
spectrometer (RP-HPLC–MS/MS) in electrospray ionisation mode (ESI) using matrix matched standards.
Based on the performance characteristics presented, the EURL recommends for ofﬁcial control the RP-
HPLC–MS/MS method proposed by the Applicant or any equivalent other analytical methods complying
with the requirements set by Commission Decision 2002/657/EC, to enforce the MRLs of monensin
sodium and nicarbazin in the target tissues.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005) is not
considered necessary.
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